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A B S T R A C T
Background
Preparing the cervix prior to surgical abortion is intended to make the procedure both easier and safer. Options for cervical preparation
include osmotic dilators and pharmacologic agents. Many formulations and regimens are available, and recommendations from pro-
fessional organizations vary for the use of preparatory techniques in women of different ages, parity or gestational age of the pregnancy.
Objectives
To determine whether cervical preparation is necessary in the first trimester, and if so, which preparatory agent is preferred.
Search methods
We searched Cochrane, Popline, Embase, Medline and Lilacs databases for randomised controlled trials investigating the use of cervical
preparatory techniques prior to first trimester surgical abortion. In addition, we hand-searched key references and contacted authors
to locate unpublished studies or studies not identified in the database searches.
Selection criteria
Randomised controlled trials investigating any pharmacologic or mechanical method of cervical preparation, with the exception of
nitric oxide donors (the subject of another Cochrane review), administered prior to first trimester surgical abortion were included.
Outcome measures must have included the amount of cervical dilation achieved, the procedure duration or difficulty, side-effects,
patient satisfaction or adverse events to be included in this review.
Data collection and analysis
Trials under consideration were evaluated by considering whether inclusion criteria were met as well as methodologic quality. Fifty-
one studies were included, resulting in 24 different cervical preparation comparisons. Results are reported as odds ratios (OR) for
dichotomous outcomes and weighted mean differences for continuous data.
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Main results
When compared to placebo, misoprostol (400-600 µg given vaginally or sublingually), gemeprost, mifepristone (200 or 600 mg),
prostaglandin E and F2α (2.5 mg administered intracervically) demonstrated
larger cervical preparation effects.Whenmisoprostol was compared to gemeprost, misoprostol was more effective in preparing the cervix
and was associated with fewer gastrointestinal side-effects. For vaginal administration, administration 2 hours prior was less effective
than administration 3 hours prior to the abortion. Compared to oral misoprostol administration, the vaginal route was associated with
significantly greater initial cervical dilation and lower rates of side-effects; however, sublingual administration 2-3 hours prior to the
procedure demonstrated cervical effects superior to vaginal administration.
When misoprostol (600 µg oral or 800 µg vaginal) was compared to mifepristone (200 mg administered 24 hours prior to procedure),
misoprostol had inferior cervical preparatory effects. Compared to day-prior laminaria tents, 200 or 400 µg vaginal misoprostol showed
no differences in the need for further mechanical dilation or length of the procedure; similarly, the osmotic dilators Lamicel and Dilapan
showed no differences in cervical ripening when compared to gemeprost, although gemeprost had cervical effects which were superior
to laminaria tents. Older prostaglandin regimens (sulprostone, prostaglandin E2 and
F2α) were associated with high rates of gastrointestinal side-effects and unplanned pregnancy expulsions. Few studies reported women’s
satisfaction with cervical preparatory techniques.
Authors’ conclusions
Modern methods of cervical ripening are generally safe, although efficacy and side-effects between methods vary. Reports of adverse
events such as cervical laceration or uterine perforation are uncommon overall in this body of evidence and no published study
has investigated whether cervical preparation impacts these rare outcomes. Cervical preparation decreases the length of the abortion
procedure; this may become increasingly important with increasing gestational age, as mechanical dilation at later gestational ages takes
longer and becomes more difficult. These data do not suggest a gestational age where the benefits of cervical dilation outweigh the
side-effects, including pain, that women experience with cervical ripening procedures or the prolongation of the time interval before
procedure completion. Mifepristone 200 mg, osmotic dilators and misoprostol, 400µg administered either vaginally or sublingually,
are the most effective methods of cervical preparation.
P L A I N L A N G U A G E S U M M A R Y
Preparing the cervix before first trimester surgical abortion
Preparing the cervix to make it softer and more open before a woman has an abortion may make the procedure easier and safer. There
are different techniques for preparing the cervix before abortion, including several types of medications taken either by mouth, injection
or placed in the vagina, as well as several types of small rods that can be placed within the cervix. This review found that cervical
preparation decreased the length of time necessary for an abortion procedure, but did not seem to decrease rates of uncommon abortion
complications. The medication called misoprostol worked better with less side-effects than other similar medications. Misoprostol is
most effective with the least side-effects when placed in the vagina, but when placed under the tongue it is equally effective. Another
drug called mifepristone worked better than misoprostol; however, it is more expensive to use. All methods of preparation take at least
2-3 hours or more to work. The review could not determine whether women preferred one method best.
B A C K G R O U N D
Vacuum aspiration is a common method of first-trimester abor-
tion worldwide. First-trimester surgical abortion has a low-risk
of complications [Hakim-Elahi 1990] however, cervical injury,
bleeding, uterine perforation, and incomplete evacuation can oc-
cur [Cates 1983; Kulier 2001]. Risk factors for these complica-
tions include provider inexperience, increased gestational age, and
abnormal uterine anatomy [RCOG 1985, Hakim-Elahi 1990].
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Cervical preparation may reduce the complications of uterine per-
foration and cervical injury. In addition, cervical preparation may
make the procedure shorter in duration, more comfortable for the
woman, and easier to perform. For these reasons, the guidelines of
the Royal College of Obstetricians and Gynaecologists (RCOG)
state “cervical preparation is beneficial prior to surgical abortion
and should be routine if the woman is aged under 18 years of age
or at a gestation of more than 10 weeks” [RCOG 2004]. Similarly,
the World Health Organization recommends cervical preparation
for women with durations of pregnancy over 9 completed weeks
for nulliparous women, for women younger than 18 years old and
for all women with durations of pregnancy over 12 completed
weeks [WHO 2003].
Options for cervical preparation include osmotic dilators and
pharmacologic agents. Osmotic dilators are able to produce wide
cervical dilation in a predictable fashion. Isaptent, the Nelaton
catheter and the vibrodilator were mechanical dilators used in the
past [Khanna 1980, Manabe 1981, Ng 1973]. Current devices
include laminaria, Lamicel ®, and Dilapan-S ®. Pharmacologic
agents such as misoprostol, gemeprost, mifepristone, and sodium
nitroprusside, soften the cervix and allow for easier, less forceful,
cervical dilation.
This review includes data from all available randomized controlled
trials regarding cervical preparation in first trimester abortion with
the goal of answering whether preparation is needed at all, and if
so, which preparatory agent is preferred.
O B J E C T I V E S
To compare the effect of different methods of cervical preparation
used prior to first trimester surgical abortion on the amount of
cervical dilation achieved, length of procedure, side-effects, satis-
faction, and safety. Included trials will be those evaluating cervical
preparation versus no preparation as well as comparisons between
methods.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Only randomized controlled trials are included in this review.
Types of participants
Pregnant women undergoing surgical abortion at less than 14
weeks gestation.
Types of interventions
Any type of cervical preparation, pharmacologic or mechanical,
excluding nitric oxide donors, administered prior to first trimester
surgical abortion.
Types of outcome measures
• Amount of cervical dilation achieved (passage of largest
dilator without resistance, pressure required to pass dilator)
• Procedure duration
• Procedure difficulty (various subjective scoring of providers)
• Side effects (nausea, vomiting, fever, chills, diarrhea)
• Patient’s satisfaction
• Adverse events (cervical injury [laceration, perforation, false
passage], hemorrhage (intraoperative and postoperative), uterine
perforation, incomplete abortion, infection [febrile morbidity,
need for therapeutic antibiotics], hospital admission)
Search methods for identification of studies
See: Cochrane Fertility RegulationGroupmethods used in reviews
(www.lumc.nl/1060/cochrane/)
See: Cochrane Fertility Regulation Group search strategy. We
searched the computerized databases-Cochrane Central Register
of Controlled Trials, MEDLINE, EMBASE, and POPLINE for
articles for trials of cervical preparation in first trimester surgical
abortion. We will contact corresponding authors of all included
published trials to seek other trials we might have missed. We also
will search the reference lists of included trials.
MEDLINE search used the strategy:
(first trimester OR pregnancy trimester, first) AND (abortion, in-
duced OR abortion, legal OR abortion, therapeutic OR preg-
nancy termination OR termination of pregnancy) AND (surgical
abortion OR dilation and curettage OR curettage OR vacuum
aspiration OR suction aspiration OR suction evacuation) AND
(cervical priming OR cervical ripening OR cervical dilation OR
antiprogesterone ORmifepristone ORmifegyne OR RU 486 OR
prostaglandin OR misoprostol OR dinoprostone OR carboprost
OR sulprostoneORgemeprostORmeteneprostORnitroglycerin
OR lamicel or laminaria OR dilapan OR osmotic dilator OR lam-
inaria tent) AND (randomized controlled trial [pt] OR controlled
clinical trial [pt] OR randomized controlled trials [mh] OR ran-
dom allocation [mh] OR double-blind method [mh] OR single-
blind method [mh] OR clinical trial [pt] OR clinical trials [mh]
OR (“clinical trial” [tw]) OR ((singl* [tw] OR doubl* [tw] OR
trebl* [tw]OR tripl* [tw]) AND(mask* [tw]ORblind* [tw]))OR
(placebos [mh] OR placebo* [tw] OR random* [tw] OR research
design [mh:noexp] OR comparative study [mh] OR evaluation
studies [mh] OR follow-up studies [mh] OR prospective studies
[mh] OR control* [tw] OR prospective* [tw] OR volunteer* [tw])
NOT (animals [mh] NOT human [mh]))
The POPLINE search used the strategy:
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(Abortion & Pregnancy, first trimester) & (studies / clinical trials)
The Cochrane Central Register of Controlled Trials search used
the strategy:
Abortion AND (first-trimester OR first trimester OR first-
trimester OR pregnancy trimester, first OR gestational age)
The EMBASE search used the strategy:
(Abortion OR Therapeutic abortion) AND (First trimester abor-
tion OR Gestational age) AND
(cervical priming OR cervical ripening OR cervical dilation OR
laminaria OR dilapan OR osmotic dilator) AND (Randomized
controlled trial OR Controlled study OR Clinical trial OR Ran-
domization OR Double blind procedure OR Single blind proce-
dure OR Methodology OR Comparative study OR Evaluation
OR Follow-up OR Prospective study OR Crossover procedure
OR (singl* OR doubl* OR trebl* OR tripl*) near (mask* OR
blind*) in TI, AB OR Placebo* OR Random* OR control* OR
Prospectiv* OR Volunteer*) AND Human
Data collection and analysis
Two independent reviewers evaluated the titles and abstracts iden-
tified from the literature searches and assessed relevant articles
for inclusion. First trimester surgical abortion was defined as an
abortion performed before 14 weeks gestation with either electric
or manual vacuum aspiration, or dilation and curettage. The tri-
als were critically appraised without consideration of their results
by examining the following factors: study design, randomisation
method, group allocation concealment, exclusions after randomi-
sation, loss-to-follow-up, and early discontinuation. A score for
concealment of allocation was assigned to each trial, per the crite-
ria outlined in the Cochrane Handbook:
A) adequate concealment of allocation
B) unclear whether adequate concealment of allocation
C) inadequate concealment of allocation
Only trials scoring A or B were included in the review.
Data extraction was performed independently by two reviewers
(NK,TD). Data such as country, setting, sponsor and outcomes of
interest were extracted using a form designed to capture these data.
Discrepencies were reviewed and resolved by the two individuals
extracting the data.
The data were analyzed using RevMan 5.0 software.
R E S U L T S
Description of studies
See:Characteristics of included studies; Characteristics of excluded
studies; Characteristics of ongoing studies.
See:Characteristics of included studies; Characteristics of excluded
studies; Characteristics of studies awaiting classification.
From the search strategy described above, 51 studies met inclusion
criteria for this review, resulting in 24 comparisons of cervical
preparation.
Risk of bias in included studies
Randomisation and allocationmethods were not further described
inmany studies; we attempted to contact the authors in these cases
to clarify theirmethods. The number of trialswhich reported using
both adequate randomisation and allocation concealment meth-
ods (whether published or by direct communication with the au-
thor) is 17; the remainder of studies stated they were randomised,
but did not specify the method or had an unclear method of allo-
cation. Loss to follow-up and post-randomisation exclusion data
were collected from the included studies; no study had rates of
>10%.
Effects of interventions
Comparisons to placebo (Analysis 1.1; Analysis 1.2; Analysis 1.3;
Analysis 2.1; Analysis 3.1; Analysis 3.2; Analysis 4.1; Analysis 5.1;
Analysis 5.2; Analysis 6.1; Table 1, Table 2)
There were significant differences in initial cervical dilation and/
or need for further cervical dilation at the time of surgical abortion
when misoprostol (400-600 µg given vaginally or sublingually),
gemeprost, mifepristone (200 or 600 mg), prostaglandin E and
F2α (2.5 mg intracervical) were compared to placebos among 18
different studies. Additionally, the length of the procedure was de-
creased with use of misoprostol when compared to placebo (mean
difference -1.09 [95%CI -1.55, -0.64]) although side-effects, such
as nausea, were generally higher in the misoprostol group.
Misoprostol comparisons
Dose of misoprostol (Analysis 7.1; Analysis 7.2; Analysis 7.3)
Improved initial cervical dilation was demonstrated with 400 µg
oral misoprostol when compared with 200 µg (mean difference
0.53 [95% CI 0.30, 0.77]) (Ngai 1999; Oppegaard 2004). When
the same doses were administered vaginally, similar results were
found (mean difference 0.92 [95% CI 0.53, 1.31]), although sig-
nificant heterogeneity is present between these data from two tri-
als (Ngai 1999; Singh 1998). dilation was also greater with a 400
µg dose of sublingual misoprostol compared to 200 µg (mean dif-
ference 2.20 [1.61, 2.79]) (Vimala, Mittal 2004). With a 400 µg
dose of sublingual misoprostol, the abortion procedure took less
time (RR -1.22 [95%CI -1.72, -0.71]); however, women reported
more pain (RR2.50 [95%CI 1.31, 4.75]) than those who received
a 200 µg dose.
Timing of misoprostol (Analysis 8.1; Analysis 8.2; Analysis 8.3)
The effect of the interval between misoprostol administration and
the procedure on cervical priming was investigated in one study
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(Singh 1999). A significant improvement in initial cervical dila-
tion (mean difference1.50 [95% CI 1.42, 1.58]) and less need for
further dilation (RR 0.01 [95%CI 0.00, 0.08]) was demonstrated
with an interval of 3 hours after 400 µg of vaginal misoprostol
when compared with an interval of 2 hours after 600 µg vaginal
misoprostol. Women who received 600 µg also reported pain with
cervical priming more frequently (RR 0.10 [95% CI 0.02, 0.39])
than women who received 400 µg of misoprostol.
Route of administration of misoprostol (Analysis 9.1; Analysis 9.2;
Analysis 9.3; Analysis 9.4; Analysis 9.5; Analysis 9.6)
Vaginal versus oral
Many studies have compared the vaginal and oral routes of miso-
prostol administration. Three studies used 400 µg, and were in-
cluded in a meta-analysis (Cakir 2005; Ngai 1999). Three other
studies compared doses ranging from 200 to 800 µg or assessed
differing times of administration between oral and vaginal admin-
istration using the same dose (Ashok 2003; Carbonell 2001; Inal
2003; Oppegaard 2006). These studies are summarised in Table 3.
Compared to oral administration, the vaginal route was associated
with significantly greater initial cervical dilation (mean difference
0.50 [95% CI 0.13, 0.87]) in the meta-analysis.
Vaginal versus sublingual
Sublingual versus vaginal administration of 400 µgmisoprostol has
been compared in four studies (Esteve 2006; Tang 2004; Vimala
2004, Hamoda 2004). One study was not included in the meta-
analysis of cervical effect as its data were reported incompletely
(Hamoda 2004, Table 3). In the meta-anlaysis, significant hetero-
geneity was noted. A sensitivity analysis demonstrated that with-
out the data fromVimala 2004 the effect estimate was -0.09 [95%
CI -0.18, -0.01] in favor of sublingual application of misoprostol
administered for 2-3 hours. When all studies were included in the
analysis, the overall estimate of effect was larger, but consistent in
demonstrating a greater effect on initial cervical dilation of sublin-
gual misoprostol (mean difference -0.10 [95% CI -0.19, -0.01])
than vaginal misoprostol administration.
Sublingual misoprostol was similarly found to be associated with
less need for further dilation (RR 1.41 [95% CI 1.15, 1.73]) than
with vaginal misoprostol, in a meta-analysis. Sublingual adminis-
tration was also associated with a higher occurrence of nausea than
vaginal administration (RR 0.33 [95% CI 0.22, 0.49]), although
no significant differences were noted between oral and vaginal
groups (RR 0.59 [95% CI 0.26, 1.37]). Additionally, sublingual
administrationdemonstrated significantly shorter procedure times
(mean difference 0.38 [95% CI 0.11, 0.65]) when compared to
vaginal administration while no differences in procedure length
were noted between vaginal and oral administration.
One small study (Hamoda 2004) attempted to address women’s
level of satisfaction with her cervical ripening method; no dif-
ferences in disatisfaction were noted between those who received
misoprostol vaginally when compared with those who received it
sublingually (RR 0.10 [95% CI 0.01, 1.97]).
Misoprostol versus gemeprost (Analysis 10.1; Analysis 10.2; Analysis
10.3; Analysis 10.4; Table 4)
Misoprostol, 400 µg, when compared to gemeprost, 1 mg, appears
to be superior in terms of cervical dilation effect (mean difference
0.53 [95% CI 0.03, 1.04]) among 2 trials included in the meta-
analysis (Ekerhovd 2003; Ngai, Yeung 1995), whereas 200 µg
misoprostol had similar effects to 1mggemeprost (meandifference
0.40 [95%CI -0.16, 0.96] [Henry 1999]).One study,which could
not be included in the meta-analysis, demonstrated no difference
between 600 µg of misoprostol and gemeprost (El-Rafaey 1994).
In comparison to gemeprost, misoprostol, 400 µg, had lower over-
all rates of gastrointestinal side-effects (RR 0.35 [95% CI 0.18,
0.68]); a similar effect estimate was found when 200 µg miso-
prostol was used (RR 0.35 [95% CI 0.18, 0.68]). The length of
the procedure was significantly reduced with 400 µg misoprostol,
when compared to gemeprost (mean differerence -1.50 [95% CI
-3.00, 0.00]).
Misoprostol versus mifepristone (Analysis 11.1; Analysis 11.2)
Mifepristone, 200 mg given 24 hours prior to the procedure, had
a greater cervical ripening effect thanmisoprostol, 600 µg orally or
800 µg vaginally (mean difference -0.79 [95% CI -1.29, -0.30] [
Ashok 2000; Bokstrom 1998]).No differences in nausea/vomiting
between the treatment groups were reported (RR 0.75 [95% CI
0.17, 3.33]).
Misoprostol versus laminaria (Analysis 12.1; Analysis 12.2; Analysis
12.3)
When 200 or 400 µg vaginal misoprostol was compared to day-
prior placement of one laminaria tent, there was no difference in
the need for further mechanical dilation (OR 1.04 [95% CI 0.48,
2.26]) or length of the procedure (mean difference -0.10 [95% CI
-1.09, 0.89] [MacIsaac 1999; Burnett 2005]). Women were asked
about their level of satisfaction with their cervical ripeningmethod
in both trials. In one, women reported favoring misoprostol over
laminaria if they were to have a procedure in the future (RR 0.31
[95%CI 0.12, 0.84] [Burnett 2005]); the other trial reported only
that <10% of women in both treatment groups were dissatisfied
with their method of cervical dilation (MacIsaac 1999).
Misoprostol versus prostaglandin F2α (Analysis 13.1; Analysis 13.2;
Analysis 13.3; Analysis 13.4; Analysis 13.5)
One study compared misoprostol to prostaglandin F2α (Vimala
2005).No significant differenceswere noted in the need for further
cervical dilation (RR 0.48 [95% 0.16, 1.41]), rates of nausea and
vomiting (RR 0.14 [95% CI 0.02, 1.23]), or the time required
to complete the procedure (mean difference 0.20 [95% CI -0.76,
1.16]). Additionally, women reported no differences in satisfaction
with misoprostol or prostaglandin F2α (RR 0.23 [95% CI 0.04,
1.24]).
Gemeprost comparisons
Gemeprost versus Lamicel ® (Analysis 14.1; Analysis 14.2)
In addition to comparisons with placebo and misoprostol, geme-
prost has been compared to several types of osmotic dilators. No
differences in the need for further cervical dilation (RR 0.86 [95%
CI 0.38, 1.95]) was reported when gemeprost was compared to
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Lamicel (Golland 1989; Stornes 1991). Additionally, use of geme-
prost was associated with lower rates pain during cervical prepara-
tion (RR 3.53 [95% CI 1.40, 8.90]) when compared to Lamicel,
although no significant differences were noted in rates of nausea
and vomiting (RR 6.89 [95% CI 0.83, 57.41]) during cervical
preparation.
Gemeprost versus Dilapan-S ® (Analysis 15.1; Analysis 15.2)
No differences in need for further dilation between those who re-
ceived gemeprost or Dilapan was noted (RR 0.87 [95% CI 0.32,
2.36]) in 2 studies (Jurgenson 1989; Golland 1989). Rates of nau-
sea between women who received Dilapan and gemeprost were
not significantly different (RR 0.83 [95% CI 0.35, 1.95]).
Gemeprost versus laminaria (Analysis 16.1; Analysis 16.2; Analysis
16.3)
When gemeprost and laminaria were compared (WHO 1986), the
need for further cervical dilation in the gemeprost group demon-
strated a significant reduction when compared to placement of
laminaria (RR 0.56 [95% CI 0.29, 1.07]). Initial cervical dilation
was found to be significantly greater in the gemeprost group when
compared to the laminaria group (mean difference 0.50 [95% CI
0.05, 0.95]). Nausea and vomiting following application of lam-
inaria was significantly less common than with use of gemeprost
(RR 18.16 [95% CI 1.04, 318.09]).
Gemeprost versus prostaglandin F2α (Analysis 17.1; Analysis 17.2;
Analysis 17.3)
Gemeprost was superior to prostaglandin F2α in terms of need
for further cervical dilation (RR 0.31 [95% CI 0.15, 0.66]) and
initial cervical dilation (mean difference 0.90 [95%CI 0.42, 1.38]
[WHO 1986]). No differences between groups were noted in
the occurrence of nausea and vomiting (RR 1.67 [95% CI 0.53,
5.25]).
Mifepristone comparisons: doses (Analysis 18.1; Analysis 18.2)
Doses of 100 mg and 25 mg mifepristone were compared in one
study (WHO1990). No significant differences between treatment
groups in cervical dilation (mean difference 0.00 [95% CI -0.74,
0.74]) or the need for futher dilation (RR 0.74 [95% CI 0.12,
4.62]) were demonstrated.
Laminaria comparisons
Laminaria versus prostaglandin F2α (Analysis 19.1; Analysis 19.2;
Table 5)
One study compared the use of laminaria placed 3-4 hours prior
to the procedure to that of prostaglandin F2α (Morris 1986): these
data are reported in table 5. The study authors reported a signifi-
cantly (p<0.01) greater effect of laminaria on initial cervical dila-
tion when compared to prostaglandin F2αhowever given the pre-
sentation of the data without standard deviations, we were unable
to calculate an effect estimate. Additionally, prostaglandin F2α was
associated with more unplanned expulsions of the pregnancy prior
to the procedure (RR 0.07 [95% CI 0.00, 1.34]).
Laminaria versus sulprostone (Analysis 20.1; Analysis 20.2; Analysis
20.3)
In comparison with sulprostone, laminaria had significantly less
effect on initial cervical dilation (mean difference -0.80 [95% CI
-1.27, -0.33]) as well as on the need for further dilation (RR
2.38 [95% CI 1.26, 4.47]) (WHO, 1986). Use of sulprostone,
however, had significantly higher rates of nausea and vomiting
than laminaria (RR 0.02 [95% CI 0.00, 0.39]).
Laminaria versus prostaglandin E2. (Analysis 21.1; Analysis 21.2;
Analysis 21.3)
The prostaglandin, 9 deoxo-16, 16-dimethyl-9-methylene PGE2,
was compared to laminaria in one trial (WHO 1986). The ef-
fects on initial cervical dilation and need for further dilation were
not significantly different, although approaching significant val-
ues in favour of a greater effect from the prostaglandin E2. Nau-
sea and vomiting were more common in the group receiving the
prostaglandin E2 (RR 0.03 [95% CI 0.00, 0.51]) when compared
to those who received laminaria.
Sulprostone comparisons
Sulprostone dosing by intracervical administration (Analysis 22.1;
Analysis 22.2; Analysis 22.3 and Table 6)
Sulprostone doses have been compared in three studies; in two
(Rath 1983; Rath 1985), intracervical doses were compared and
in one study, intramuscular doses were compared (Christensen
1985). For intracervical doses of either 50 or 100 µg administered
6-8 hours prior to the procedure, no differences in cervical effects
or in rates of nausea/ vomiting (RR0.79 [95%CI0.21, 3.04])were
detected. Differences were noted, however, in the occurrence of
unplanned expulsion prior to the abortion procedure: significantly
higher rates of unplanned expulsion occurred with the 100 µg
dose when compared with the 50 µg dose of sulprostone (RR 0.04
[95% CI 0.00, 0.37]).
Sulprostone dosing by intramuscular administration (Analysis 23.1;
Analysis 23.2;Analysis 23.3)
When dosing by intramuscular injection was used 3-4 hours prior
to the procedure, no differences in cervical effect were noted be-
tween 250 µg and 500 µg of sulprostone (RR 0.72 [95% CI 0.24,
2.15]). Nausea and vomiting did differ between the doses with
significantly higher rates occurring in the 500 µg group (RR 0.13
[95% CI 0.04, 0.44]). One unplanned expulsion occurred in the
higher dose group, while none occurred among those who received
the lower dose (RR 0.34 [95% CI 0.01, 8.36]).
PGE2 comparisons
Prostaglandin E2 versus prostaglandin F2α (Analysis 24.1; Analysis
24.2; Analysis 24.3)
One study compared prostaglandins E2 and F2α (Heinzl 1981).
Women who received 1mg oral prostaglandin E2 required more
mechanical cervical dilation than women receiving 2.5 mg in-
tracervical prostaglandin F2α (RR 12.90 [95% CI 7.22, 23.05]).
However, they experienced less nausea (RR 0.17 [95% CI 0.04,
0.78]) and had significantly fewer unplanned expulsions prior to
the procedure (RR 0.01 [95% CI 0.00, 0.23]) than those in the
prostaglandin F2α group.
Lamicel comparisons (Analysis 25.1)
Lamicel® versus cervical tents without MGSO4 (Table 7)
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One study compared Lamicel to similar tents which did not con-
tain MgSO4. Data reported were not complete enough for re-
analysis, but initial cervical dilation between the two groups was
similar. Additionally, the occurrence of unplanned expulsion prior
to the procedure was similar between treatment groups (RR 3.65
[95% CI 0.14, 94.97]).
D I S C U S S I O N
The quality of evidence included in this review is mixed; however,
the more recent studies are generally of good or fair quality. To
improve the quality of evidence we reviewed, we excluded studies
with evidence of bias, either in the methodology of randomisation
or concealment of allocation. Since assessment of cervical dilation
and any immediate, procedure-related complications occur at the
time of the procedure, loss to follow-up in included studies did not
introduce a significant source of bias. In addition, we attempted
to reduce bias from our assessment and analyses of the evidence
by assessing articles for inclusion in the review and extraction of
data by two independant researchers.
There are many safe methods of cervical ripening prior to surgical
abortion, although efficacy and side-effects betweenmethods vary.
Reports of adverse events such as cervical laceration or uterine per-
foration are uncommon in this body of evidence and no study has
investigated whether cervical preparation impacts these rare out-
comes among women having first trimester abortion procedures.
Cervical preparation decreases the length of the abortion proce-
dure; this may become increasingly important with increasing ges-
tational age, as mechanical dilation at later gestational ages takes
longer and becomes more difficult. The decreased procedural time
may have very little impact on procedures at early gestation which
already take very little time to perform. These data do not suggest
a gestational age where the benefits of cervical dilation outweigh
the side-effects, including pain, that women experience with cer-
vical ripening procedures or the prolongation of the time interval
before procedure completion.
Few studies have evaluated women’s satisfaction or perception of
cervical ripening procedures. It is difficult to assess women’s pref-
erences, particularly in randomised trials where a woman expe-
riences only one method of cervical preparation; in three of the
four trials that investigated this outcome, there were no differences
between treatment groups and women’s disatisfaction with their
cervical ripening method. In one trial, women reported higher
rates of dissatisfaction with use of laminaria when compared to
misoprostol.
When prostaglandins are compared, misoprostol is superior to
gemeprost in terms of cervical ripening effect and in decreasing
the occurrence of side-effects. Two trials demonstrated, however, a
greater effect of mifepristone when compared tomisoprostol, with
no differences in side-effects. Misoprostol appears to be equally
effective as laminaria in the studies included in this review. The
dose of 400µg is superior to 200µg in terms of effects on the cervix.
Routes of administration may be sublingual, which is superior to
vaginal in terms of cervical effect, or vaginal, which is superior in
terms of limiting side-effects.
All methods of preparation prior to the surgical procedure require
3 hours to be most efficacious, with the exception of sublingual
misoprostol whichmay be effective at 2 hours after administration.
For methods such as osmotic dilators or mifepristone, more time
is needed. Particularly when prostaglandins are used, this time pe-
riod of cervical preparation can be painful for women, and can be
associated with gastrointestinal side-effects. Older prostaglandins,
particularly at higher doses or over longer time periods, were as-
sociated with unplanned expulsion of the pregnancy prior to the
surgical procedure; this appears to occur infrequently when miso-
prostol is administered 3 hours prior to the abortion procedure.
The conclusions of this review agree with themost recent review of
cervical dilation techniques prior to 14 weeks gestation, published
by the Society for Family Planning 2007 (Allen 2007). Although
RCOG 2004 and WHO 2003 recommends adolescents receive
cervical preparation prior to abortion procedures, no randomised
trials have compared the rates of adverse outcomes of adolescents
with those of adult women.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Misoprostol is the preferred prostaglandin for cervical ripening.
If misoprostol is used, it should be given adequate time to have
maximum effect (3 hours for vaginal administration, 2 hours for
sublingual) without extending the time to the point where un-
planned expulsions begin to occur (6-8 hours or overnight use).
When adequate time elapses between administration and the sur-
gical procedure, lower doses are as effective with lower rates of
side-effects. Laminaria have a cervical ripening effect with gener-
ally lower rates of gastrointestinal side-effects and greater rates of
insertional pain; their use may be limited in women who prefer a
same-day procedure. Mifepristone may be superior to misoprostol
in terms of cervical preparation, however, its use may be limited
by its current high cost and time required for effect (24 hours).
Implications for research
Research should attempt to delineate the gestational age where
cervical preparation decreases adverse events and whether there are
groups of women where cervical preparation is particularly impor-
tant (adolescents or nulliparae). Additionally, the use of mifepris-
tone for cervical preparation in the later first trimester should be
investigated. Women’s preferences for cervical preparatory tech-
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niques have been inadequately explored and should be included
in future research.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Aronsson 2004
Methods Randomisation method not described. Allocation using sealed, sequentially numbered envelopes
Participants 32 women
Included: women between 8 and 12 weeks of pregnancy. Exclusion criteria: prior delivery/abortion,
abnormal pregancy, contraindication to misoprostol, signs of genital infection
Hospital setting, Sweden.
Interventions Intervention 1: 400 µg misoprostol administered orally 3 h prior to surgery
Intervention 2: 400 µg misoprostol administered sublingually 3 h prior to surgery
Outcomes Pre-operative cervical dilation, blood loss
Notes Sealed envelopes did not stipulate that theywere opaque. Attempted to clarify randomisation and allocation
with author but received no response
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear B- unclear
Ashok 2000
Methods Randomisation using sequentially numbered, sealed, opaque envelopes that had been prepared using a
random number table
Participants 90 women.
Included: women who underwent vacuum aspiration abortion, 15-40 years old, between 6.6 and 12.
1 weeks gestation age, with no contraindications to prostaglandin or mifepristone. Exculsion criteria:
symptoms or signs of a threatened miscariage, history of cervical surgery, or women living ≥1 hour away
from the hospital
Hospital setting, Scotland.
Interventions 1) 800 µg vaginal misoprostol 24 h prior to procedure; 2) 200 mg mifepristone 24 h prior to procedure;
3) 200 mg mifepristone 48 h prior to procedure
Outcomes Initial cervical dilation, need for further dilation, force needed for dilation, blood loss, acceptibility
Notes
Risk of bias
Item Authors’ judgement Description
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Ashok 2000 (Continued)
Allocation concealment? Yes A-Adequate
Ashok 2003
Methods Randomisation by random number tables and allocation by sequentially numbered, opaque, sealed en-
velopes
Participants 64 women
Included: women in in their first pregnancy over 16 years, singleton viable intrauterine pregnancy at
gestations up to 91 days, no contraindication to prostaglandins. Exclusion criteria: threatened miscarriage
or hemorrhagic disorders
Hospital setting, Scotland.
Interventions 1) misoprostol 400 µg orally at home; 2) Two tablets of misoprostol 400 µg vaginally in the hospital 2-
4hours pre-operative
Outcomes Efficacy (initial dilation and force needed), side-effects, acceptability
Notes No cervical lacerations or perforations occurred.
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Yes A-Adequate
Bokstrom 1998
Methods Randomised in a double-blinded manner (not otherwise specified)
Participants 45 women.
Included: nulliparae between 8 to <10 weeks gestation. Gestational age confirmed by ultrasound
Hospital setting, Sweden
Interventions Treated with 1) misoprostol orally (600 µg) 16 to 20 h before surgery 2)
mifepristone (200 mg) 48 and 24 h before surgery or 3) placebo
Outcomes Side effects and pain, degree of cervical dilation, immunohistochemistry
Notes Attempted to clarify randomisation and allocation with author but received no response
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear B-Unclear
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Burnett 2005
Methods Randomisation by coin toss. Open-label.
Participants 70 women.
Included: healthy women <15 weeks gestation. Exclusion criteria: not stated
Canada, unclear setting
Interventions 1) misorpostol 200 µg vaginally; 2) Laminaria tents
Outcomes Degree of dilation
Notes
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear B-Unclear
Cakir 2005
Methods Computer-based restricted stratified randomisation was generated, and sealed envelopes were used for
allocation concealment. Placebo-controlled trial
Participants 160 women randomised.
Included: women at 7-10 weeks gestation with singleton pregnancy. Exclusion criteria: systemic disease,
contraindication for misoprostol, history cervical surgery (major or minor), threatened or missed abor-
tion or initialinitial cervical dilation, Hgb<10, bleeding or spotting during current pregnancy, multiple
pregnancy, basal cervical dilation greater than 4mm. Confirmed gestational age by US
Family planning clinic, Turkey.
Interventions Three hours prior to procedure: 1) oral placebo 2) vaginal placebo 3) oral misoprostol 400 µg 4) vaginal
misoprostol 400 µg
Outcomes Side effects, blood loss, degree of cervical dilation
Notes Sealed envelopes did not stipulate that they were opaque or sequentially numbered
Reported no unplanned expulsions of the pregnancy before scheduled procedure and no hospitalizations
for complications
Two women who received oral misoprostol developed fevers.
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear B- unclear
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Carbonell 2001
Methods Randomisation method not specified. Allocation using sealed, opaque, sequential envelopes
Participants 900 women.
Included: women at least 18 years of age, gestational age up to 63 days, ability of the woman to give
informed consent, to understand and complete the protocol, and willingness to abstain from sexual
intercourse for the first 14 days of the study. Exclusion criteria: Hgb < 10, HTN, threatened/ ongoing
abortion, contraindication to misoprostol, active gential infection. Confirmed gestational age by US
Maternity hospital, Cuba.
Interventions 400 µg misoprostol administrered 1) orally 8 h prior 2) vaginally 4 h prior
Outcomes Cervical dilation, side-effects, blood loss
Notes 2 women who received oral misoprostol had unplanned expulsions prior to the procedure
No cervical lacerations or perforations occurred.
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Yes A-Adequate
Cheng 1975
Methods Double-blinded randomised controlled trial (method not specified)
Participants 50 women.
Included: women aged 15-29 with gestational ages 7-12 weeks and who were nulliparous
Hospital setting, Singapore
Interventions Twenty hours before procedure: 1) 25 µg 15 methyl PGE2 methyl ester administered extra-amniotically
2) 2 ml normal saline
Outcomes Side effects, cervical dilation
Notes Attempted to clarify randomisation and allocation with author but received no response. There were 3
cervical lacerations in the placebo group
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear B- Unclear
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Christensen 1984
Methods Randomised controlled trial (not otherwise specified).
Participants 134 women randomised. Mean gestation 69-71 (51-119) days. Included nulliparous healthy women,
gestational age <13 weeks , no signs of threatened abortion
Hospital setting, Sweden
Interventions 3 hours prior to procedure, women received either 1)16,16-dimethyl-trans-delta2- PGE1 methyl ester 2)
placebo
Outcomes Cervical dilation, further dilation needed, blood loss
Notes Attempted to clarify randomisation and allocation with author but received no response. No cervical
lacerations occurred. Two uterine perforations occurred in the placebo group
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear B- Unclear
Christensen 1985
Methods Randomised controlled trial
Participants 200 women.
Included: women in 8-12th week pregnancy with average age 22-23 years and average gestational age 10
weeks
Hospital setting, Sweden
Interventions 3-4 h before procedure intramuscular sulprostone 1) 250 µg 2) 500 µg
Outcomes Side-effects, cervical dilation
Notes Attempted to clarify randomisation and allocation with author but received no response. No cervical
lacerations occurred. One uterine perforation occurred in the 500 µg group
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear B- Unclear
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de Jonge 2000
Methods Double-blind, randomised (using permuted size 8 blocks for the first 152 women but not for the following
118) placebo-controlled trial
Participants 278 women randomised.
Included: gestational age<13 weeks (average gestational age of 62 days, average age 27-28). Exclusion
criteria: symptomatic asthma/cardiac disease, anticoagulant therapy or Hgb<8, other serious medical
conditions. Gestational age confirmed by US
Hospital setting, South Africa.
Interventions 2-3 hours prior to procedure: 1) 600 µg misoprostol vaginally or 2) placebo (750 mg ascorbic acid)
Outcomes Degree of cervical dilation
Notes
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Yes A-Adequate
Durlot 1988
Methods Double-blinded randomised controlled trial (methods not specified) using a non-algorithmic randomisa-
tion method, per study authors. This method was not further described
Participants 64 women randomised.
Included women between 6-12 weeks gestation. Exclusion criteria: women with liver, GI or renal disease
or having received corticosteriods last 3 month
Hospital setting, France
Interventions 2 days prior to procedure women received: 1) placebo 2) mifepristone 200 mg/ day
Outcomes Cervical dilation
Notes
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Yes A- Adequate
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Ekerhovd 2003
Methods Randomisation by sealed, opaque sequential envelopes prepared using random number tables
Participants 90 women randomised.
Included women who were healthy and nulliparous with singleton pregnancy, 8-12 weeks’ gestation. Ex-
cluded women with threatened abortion or any kind of chronic disease (requiring daily meds). Confirmed
dating by US
Hospital setting, Sweden
Interventions 3-4 h prior to procedure, women receieved either: 1) 1 mg gemeprost or 2) 400 µg misoprostol
Outcomes Cervical dilation and peak force to dilate
Notes No cervical lacerations or uterine perforations occurred.
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Yes A-Adequate
El-Rafaey 1994
Methods Randomisation using computer-generated random number tables.
Participants 90 women randomised.
Included: nulliparous women with pregnancies between 9-13 weeks. Excluded: women with history of
cervical surgery or threated abortion
Hospital setting, Scotland
Interventions 2-4 h prior to procedure women received vaginally: 1) gemeprost 1mg 2) misoprostol 600 µg or 3) placebo
Outcomes Side-effects, cervical dilation, blood loss, biopsy specimens
Notes One cervical laceration and one hospitalization occurred in the placebo group. No uterine perforations
occurred
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear B- Unclear
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Esteve 2006
Methods Computer-generated randomisation with allocation using sealed, opaque sequential envelopes
Participants 1424 women randomised.
Average gestation 55 days. Included: healthywomen nomore than 84 days gestation, willingness to abstain
from sex for 14 days after abortion, and ability to give informed consent. Exclusion for Hgb <10, HTN
(≥160-90), threatened abortion (prior uterine bleeding), active genital infection, suspected ectopic, or
intolerance to misoprostol. Gestational age confirmed by US
Clinics in Spain.
Interventions Misoprostol 400 µg 1-3 h before procedure, administered 1) sublingually 2) vaginally
Outcomes Cervical dilation, side-effects, length of procedure
Notes No cervical lacerations or uterine perforations occurred. One hospitalization occurred
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Yes A- Adequate
Golland 1989
Methods Randomised by random number generation.
Participants 66 women randomised.
Included nulliparous women between 7-14 weeks gestation aged 16-28 years. Excluded those with a
history of cervical surgery
Hospital setting, UK
Interventions 3 hour prior to procedure women received: 1) gemeprost 1 mg 2) 3mm Lamicel dilator 3) 4mm Dilapan
Outcomes Degree of cervical dilation
Notes Surgeon blinded to treatment group. Two cervical lacerations occurred. There were no uterine perforations,
hospitalizations or infections
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear B- unclear
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Gupta 1990
Methods Randomised, placebo-controlled study using a stratified randomisation code
Participants 30 women randomised.
Included: women up to 91 days gestation aged 18-39. Excluded: women with multiple gestations, ec-
topic pregancy, missed abortion, threatened abortion, previous cervical surgery, serious medical illness, or
treatment with steriods in last 6 months
Hospital setting, UK.
Interventions 42-53 h before procedure, women received: 1) placebo or 2) mifepristone 600mg orally
Outcomes Cervical dilation, blood loss
Notes A third party held the allocation code.
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear B- unclear
Hamoda 2004
Methods Randomised by sequential, opaque sealed envelopes generated by random number tables
Participants 74 women were randomised.
Included: women who were nulliparous, with singleton pregnancy in first trimester. Excluded: women
with previous cervical surgery, contraindication to misoprostol, or a previous pregnancy. Gestational age
confirmed by US
Hospital setting, Scotland.
Interventions 2-4 h prior to surgery, women received misoprostol 400 µg either: 1) sublingually or 2) vaginally
Outcomes Bleeding, side-effects, cervical dilation
Notes No cervical lacerations, uterine perforations, hospitalizations or infections occurred
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Yes A-adequate
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Heinzl 1981
Methods Randomisation using a random number table. The trial was double-blinded
Participants 581 women randomised.
The average gestation was between 9-10 weeks. Included women up to 12 weeks (7-12 weeks) gestation
Hospital setting, Switzerland.
Interventions Administered approximately 16 h prior: 1) 1 mg prostaglandin E2 orally 2) 2.5 mg prostglandin F2 alpha
intracervically 3) placebo intracervical gel or 4) nothing
Outcomes Cervical dilation
Notes Author contacted to provide the methods of randomisation and allocation
No uterine perforations occurred. Two infections (one each in the oral PGE group and placebo group)
and 1 hospitalization (oral PGE group) occurred
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear B- Unclear
Henry 1999
Methods Randomisation generated by random number tables (with block size of 20) and allocated using sealed
envelopes
Participants 199 women randomised.
Included: women aged 18-44 years with mean gestational age of 9.7 weeks
Maternity hospital, Finland.
Interventions Women received: 1) 200 µg vaginal misoprostol; 2) gemeprost 1 mg vaginal
Outcomes Cervical dilation, blood loss
Notes No cervical lacerations, uterine perforations or hospitalizations occurred
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear B- Unclear
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Ho 1983
Methods Double blinded placebo-controlled trial by random number generation, blocks of 10
Participants 120 women randomised.
Included: women aged 21-33 with average gestational age of 10 weeks (9.1-10.3). Excluded: women with
signs of threatened abortion, history of atopy or serious medical disease or pregnancy beyond first trimester
Hospital setting, Hong Kong.
Interventions 3 h prior to procedure, women received 1) 1 mg 16, 16,-dimethyl-trans delta2- porostaglandin E1methyl
ester or 2) placebo
Outcomes Side-effects, cervical dilation, blood loss, complications
Notes One cervical laceration in the placebo group occurred. There were no uterine perforations
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Yes A-Adequate
Inal 2003
Methods Double-blinded, randomised controlled trial (method not described)
Participants 120 women. Included: women with gestational age within the 1st trimester. Gestational age was deter-
mined by ultrasonography
Hospital setting, Turkey.
Interventions 10 h prior to procedure, received 1) 200 µg misoprostol orally 2) 200 µg misoprostol vaginally 3) oral
placebo or 4) vaginal placebo
Outcomes Cervical dilation, length of procedure, side-effects, expulsion
Notes Attempted to clarify randomisation and allocation with author but received no response
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear B- unclear
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Jurgenson 1989
Methods Randomised controlled study (method not described)
Participants 40 women randomised.
Included: healthy, nulliparous women in first trimester. Confirmed gestational age by US
Hospital setting, Sweden.
Interventions 4 h prior to procedure, women received 1) 16,16 dimethyl-trans-delta-PGE1 (Cervagem®) or 2) one
Dilapan® (4x65mm)
Outcomes Initial cervical dilation, need for additional dilation, blood loss
Notes Attempted to clarify randomisation and allocation with author but received no response
No cervical lacerations, uterine perforations or hospitalizations occurred
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear B- unclear
MacIsaac 1999
Methods Placebo-controlled double-blinded (or, at least provider-blinded) trial with randomisation performed by
using a computer-generated, random-number-producing algorithm with randomly permuted fixed blocks
of seven. Allocation by sequential, opaque, sealed envelopes
Participants 106 women randomised. Included: women >16 years between 7-14 weeks gestation, willing to comply
with standard treatment and speaking either English or Spanish. Excluded women who were intolerant/
allergic to misoprostol, who had severe asthma or hypertension requiring daily medication. Confirmed
gestational age by US
Hospital setting, USA.
Interventions Approximately 4 h prior to procedure: 1) one medium laminaria; 2) 400 µg misoprostol vaginally; 3) 400
µg misoprostol orally
Outcomes Cervical dilation, need for additional dilation, blood loss, procedure duration, side-effects, acceptability
Notes No cervical lacerations or uterine perforations occurred. Although unplanned expulsion not reported, 5
women who received misoprostol had their procedures early due to vaginal bleeding
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Yes A-adequate
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MacKenzie 1990
Methods Randomisation by random number table
Participants 1030 women randomised.
Included: women aged 16-47 who were not more than 13 weeks gestation. Exclusion criteria not stated
Hospital setting, UK.
Interventions Morning of procedure (1-4 h prior to procedure), women received 1) 10 mg vaginal pessary of PGE2 or
2) gemeprost 1mg
Outcomes Initial dilation, need for and ease of further dilation, surgical complications (uterine/ cervical injury) and
blood loss
Notes There were 28 (gemeprost) and 33 (PGE) cervical lacerations and 7 (gemeprost) and 1 (PGE) uterine
perforations during this study
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear B- unclear
Morris 1986
Methods Randomised controlled trial
Participants 60 women.
Included: women who had not been pregnant before, were between 6-13 weeks, and had never undergone
any gynaecological surgery
Hospital setting, Australia.
Interventions 12 h prior, women received 1) laminaria 2) PGF2a gel (20 mg) 3) no treatment
Outcomes Cervial dilation, ease of further dilation, blood loss
Notes Attempted to clarify randomisation and allocation with author but received no response. No hospitaliza-
tions as a result of abortion complications. Five unplanned expulsions in PGF group
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear B- unclear
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Ngai 1995
Methods Double-blind randomised controlled trial, with randomisation and allocation performed as described in
Clinical trials: Design, conduct and analysis.
Participants 75 women randomised.
Included: women with gestations between 42-84 days
Average age 20-21 in misoprostol group and 24-25 in placebo group. Average gestational age of 9 weeks
(8.9-9.3)
Clinic setting, Hong Kong.
Interventions 12 h prior, women took 1) placebo (vitamin B) 2) misoprostol 400 µg orally
Outcomes Cervical dilation, need for further dilation, ease of dilation, blood loss
Notes One cervical laceration occurred in the placebo group. There were 2 repeat curretages for incomplete
procedure, one in each treatment group
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear B- unclear
Ngai 1999
Methods Randomised controlled trial, with randomisation and allocation performed as described in Clinical trials:
Design, conduct and analysis.
Participants 225 women randomised.
Included: nulliparous women between 56-84 days gestation with normal general and GYN history
Hospital setting, Hong Kong.
Interventions 3 h prior to procedure, women received 1) 200 µg oral misoprostol (vaginal placebo) 2) 400 µg oral
misoprostol (vaginal placebo) 3) oral placebo and 200 µg vaginal misoprostol 4) oral placebo and 400 µg
vaginal misoprostol 5) oral and vaginal placebo
Outcomes Cervical dilation, further dilation and force needed, blood loss
Notes No cervical lacerations, uterine perforations or unplanned expulsions occurred
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear B- unclear
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Ngai, Yeung 1995
Methods Randomised controlled trial, with randomisation and allocation performed as described in Clinical trials:
Design, conduct and analysis.
Participants 64 women randomised
Included: nulliparous women between 42-84 days gestation (confirmed by either physical examination
or ultrasound)
Clinic setting, Hong Kong.
Interventions 12 h prior, women took either 1) 400 µg misoprostol or 2) placebo and then 3 h prior 1 mg gemeprost
placed vaginally
Outcomes Cervical dilation, further dilation needed, blood loss
Notes No cervical lacerations, uterine perforations or hospitalizations occurred
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear B- unclear
Okanlomo 1999
Methods Double-blinded randomised trial by computer generated numbers and allocation using sealed, opaque
sequential envelopes
Participants 136 women randomised.
Included: healthy women between 6-12 weeks gestation, with no medical disorders. Excluded: women
with malodorous vaginal discharge or anxiety
Clinic setting, South Africa.
Interventions 12 h and 4 h prior, women received 1) 600 µg and 400 µg misoprostol (vaginal 1st dose, oral 2nd dose)
2) placebo
Outcomes Cervical dilation, procedure length, estimated gestational age from products of conception, and visual
analog score of pain experience
Notes No cervical lacerations or uterine perforations occurred.
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Yes A-Adequate
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Oppegaard 2004
Methods Double-blinded randomised controlled trial, with randomisation performed with permuted blocks using
a randomisation plan generator. Allocation by sealed, opaque, sequentially numbered envelopes
Participants 600 women randomised.
Included: women with viable pregnancies between 7-12 weeks. Excluded: women who did not speak
Norwegean or English, with a known allergy to misoprostol or gestational age outside of the 7-12 weeks.
Confirmed gestational age by US
Clinic setting, Norway.
Interventions The night before the procedure, women took either 1) oral misoprostol 400 µg 2) oral misoprostol 200
µg
Outcomes Cervical dilation, blood loss
Notes No unplanned expulsions occurred.
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Yes A-adequate
Oppegaard 2006
Methods Randomisation was performed with permuted blocks using a randomisation plan generator. Allocation
by sealed, opaque, sequential envelopes
Participants 338 women randomised.
Included women with viable pregnancies between 7-12 weeks. Exclusion: speaking a language other than
Norwegean or English or known allergy to misoprostol. Confirmed gestational age by US
Clinic setting, Norway.
Interventions 1) 400 µg vaginal misoprostol 2) 400 µg oral misoprostol
Outcomes Cervical dilation, pain, acceptability
Notes One cervical laceration occurred in the oral misoprostol group; there were no uterine perforations or
hospitalizations
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Yes A-Adequate
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Osmers 1990
Methods Placebo-controlled, double blinded randomised controlled trial (method of randomisation not described)
Participants 50 women randomised.
Included: nulliparous, healthy women between 7-12 weeks aged 15-38 years. Confirmed gestational age
by US
Hospital setting, Germany.
Interventions 6 h prior to procedure 1) placebo 2) intracervical gel of 500 µg PGE2
Outcomes Pain, cervical dilation, blood loss
Notes Attempted to clarify randomisation and allocation with author but received no response. One cervical
laceration occurred in the placebo group; there were no uterine perforations. Two women in the placebo
group required re-evacuation
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear B- unclear
Rabe 1985
Methods Placebo- controlled double-blinded randomised trial (randomisation method not further described)
Participants 109 women randomised.
Included: women between 9-12 weeks gestation, aged 18-42. Exclusions: threatened abortion, previous
gynaecological operation, prostaglandin allergy, cardiovascular disease, ulcerative colitis, diabetes, coagu-
lation problems, thalassaemia, renal insufficiency, glomerulonephritis, or epilepsy
Hospital setting, Germany.
Interventions 3 hours before the intervention, the medication was placed into the posterior fornix followed by 1 hour
of bedrest, either 1) Gemeprost 1mg/pv; 2) Placebo
Outcomes Status of the cervix (firm/soft/open), difficulty of dilation (subjective measurement and size of hegar
dilator), side-effects
Notes
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear B-unclear
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Radestad 1988
Methods Randomised clinical trial (method of randomisation and allocation concealment not described)
Participants 42 women randomised.
Included: women with gestational ages between 7-11 weeks. Ultrasound used to confirm gestational age
Sweden, unclear setting.
Interventions 12 and 24 h prior, women received 1) mifepristone 100 mg or 2) placebo
Outcomes Force of dilation, cervical dilation, side-effects
Notes Attempted to clarify randomisation and allocation with author but received no response. No cervical
lacerations or uterine perforations occurred
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear B-unclear
Radestad 1989
Methods Randomised controlled trial (methods of randomisation and allocation concealment not described)
Participants 45 women randomised.
Included: women with gestational age between 6-11 weeks, with no history of spontaneous abortion,
cesarean section or cervical procedures. Ultrasound used for gestational age dating
Hospital setting, Sweden.
Interventions 3-4 h prior to procedure, women received 1) Lamicel, 3 mm or 2) synthetic sponge without MgSO4
Outcomes Cervical dilation, force needed for further dilation, blood loss
Notes Attempted to clarify randomisation and allocation with author but received no response
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear B- unclear
Rath 1983
Methods Double-blinded randomised trial
Participants 30 women randomised.
Included: nulliparous women in the first trimester who were healthy, without gynaecologic or internal
disorders
Hospital setting, Germany
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Rath 1983 (Continued)
Interventions Intracervical placement 8 h prior to procedure of 1) 0.5 mg PGE2 gel 2) 0.05 mg sulprostone gel or 3)
0.1 mg sulprostone gel
Outcomes Cervical dilation, ease of passage through canal measured by tonometry, bleeding, pain, abortion
Notes Attempted to clarify randomisation and allocation with author but received no response. There were 2
cervical lacerations in the PGE2 group; no uterine perforations occurred
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear B- unclear
Rath 1985
Methods Randomised controlled trial
Participants 60 women randomised.
Included women in the first trimester with an average gestational age of 10 weeks
Hospital setting, Germany
Interventions 6-8 h prior to procedure, women received intracervical sulprostone 1) 25 µg 2) 50 µg or 3) 100 µg
Outcomes Cervical dilation, force needed to dilate, success of dilation, pain and side-effects
Notes Attempted to clarify randomisation and allocation with author but received no response. No uterine
perforations or hospitalizations occurred
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear B-unclear
Shalev 1988
Methods Double-blinded, randomised controlled trial (method not described)
Participants 40 women randomised. Included nulliparous women between 16-25 years with gestational age between
7-12 weeks
Hospital setting, Israel
Interventions Intracervical placement the night before procedure of: 1) PGE2 gel 1 mg or 2) placebo
Outcomes Cervical dilation, difficulty of procedure, side-effects
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Shalev 1988 (Continued)
Notes Attempted to clarify randomisation and allocation with author but received no response. No cervical
lacerations or uterine perforations occurred. There was one reaspiration in the placebo group
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear B-unclear
Sharma 2005
Methods Randomised controlled trial using computer-generated random number generation
Participants 90 women randomised.
Included healthy women >18 years old, between 7-10 weeks gestation who had no contraindication to
misoprostol use. Excluded women with possible threatened abortion. Confirmed gestational age dating
by ultrasound
Hospital setting, UK.
Interventions 60 minutes prior to procedure: 1) oral miso 400 µg 2) vaginal miso 800 µg 3) no treatment
Outcomes Force required to dilate cervix, initial dilation
Notes Allocation method not described. No cervical lacerations or uterine perforations occurred
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear B- unclear
Singh 1998
Methods Double-blinded randomised controlled trial; randomisation as described inClinical trials:Design, conduct
and analysis, and allocation by sealed, opaque, sequential envelopes
Participants Randomised 120 women.
Included: nulliparous women in the first trimester. Ultrasound was used to confirm gestational age
Hospital setting, Singapore
Interventions 3-4 h prior to procedure, vaginal administration of misoprostol at doses of 1) 200 µg 2) 400 µg 3) 600
µg, or 4) 800 µg
Outcomes Cervical dilation, side-effects, need for further dilation, blood loss
Notes
31Cervical preparation for first trimester surgical abortion (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Singh 1998 (Continued)
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Yes A- adequate
Singh 1999
Methods Double blinded, randomised controlled trial. Randomisation by random number tables and allocation by
sequential, sealed, opaque envelopes
Participants 60 women randomised.
Included: nulliparae between 6-11 weeks with Hgb>10. Gestational age confirmed by US or pelvic exam
Hospital setting, Singapore
Interventions Misoprostol administered either 1) 600 µg vaginally 2 h prior 3) 400 µg 3 h prior
Outcomes Cervical dilation, need for further dilation, blood loss
Notes There were no hospitalizations or unplanned expulsions.
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Yes A- adequate
Singh, Fong 1999
Methods Randomised controlled trial. Randomisation by random number tables and allocation by sequential,
opaque envelopes
Participants 180 women randomised.
Included nulliparae between 6-11 weeks gestation with Hgb>10
Hospital setting, Singapore.
Interventions Prior to procedure, women received misoprostol vaginally 1) 400 µg 3 h prior 2) 600 µg 2 h prior 3) 800
µg 2 h prior
Outcomes Cervical dilation, blood loss, successful dilation
Notes There were no unplanned expulsions.
Risk of bias
Item Authors’ judgement Description
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Singh, Fong 1999 (Continued)
Allocation concealment? Yes A- adequate
Stornes 1991
Methods Randomised clinical trial.
Participants 108 women randomised.
Included: nulliparae between 7-12 weeks who were 19-24 years old. Excluded: women with asthma,
cardiovascular insufficiency, elevated ocular pressure, or allergies to prostaglandins
Hospital setting, Denmark
Interventions 4 h prior to procedure, women received 1) gemprost vaginal pessary or 2) Lamicel tent (3mm except for
last 3 patients who received 5 mm)
Outcomes Cervical dilation, whether further dilation needed, blood loss, complications
Notes Allocation per sealed, opaque, sequential envelopes, per author. Randomisation method unclear. There
was one hospitalization in the Lamicel group
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Yes A- adequate
Tang 2004
Methods Single-blinded trial with randomisation by computer-generated random numbers
Participants 80 women randomised.
Included nulliparae <12 weeks gestation with a normal general and gynaecologic history and with a normal
physical exam. Excluded women taking long-term medication, who had an IUD in situ, who were heavy
smokers, or had an allergy to misoprostol. Ultrasound was used to confirm gestational ages in some cases
Hospital setting, Hong Kong
Interventions 3 h prior to procedure, women received 400 µg misoprostol either 1) sublingually or 2) vaginally
Outcomes Cervical dilation, force needed to further dilate, blood loss
Notes There were no cervical lacerations or uterine perforations.
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear B- unclear
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Vimala 2003
Methods Randomised controlled trial with allocation by sequential, opaque, sealed envelopes
Participants 60 women randomised.
Included women between 6-11 weeks gestation and excluded those with obstetric or gynaecologic com-
plications or an allergy to misoprostol. Ultrasound used to confirm dating in some cases
Hospital setting, India.
Interventions 2 h prior to procedure, women received either 1) 400 µg sublingual misoprostol or 2) pyridoxine (placebo)
Outcomes Side-effects, cervical dilation, need for further dilation, blood loss
Notes No uterine perforations occurred.
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Yes A- adequate
Vimala 2004
Methods Randomised controlled trial using random number table and allocation by sequential, opaque, sealed
envelopes
Participants 100 women randomised.
Included women between 6-12 weeks gestation. Excluded those with medical problems, history of cervical
surgery or cesarean or an allergy to misoprostol. Gestational age confirmed by ultrasound
Hospital setting, India.
Interventions 2 h prior to procedure, women received 400 µg misoprostol 1) sublingually or 2) vaginally
Outcomes Side- effects, cervical dilation, need for further dilation, duration of procedure, blood loss
Notes No uterine perforations occurred.
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Yes A- adequate
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Vimala 2005
Methods Randomised controlled trial using random number tables and allocated by sequential, opaque, sealed
envelopes
Participants 60 women randomised.
Included women with gestational age between 9-12 weeks. Excluded those with known heart disease,
asthma, a scarred uterus, or allergy or contraindications to prostglandins. Dating confirmed by ultrasound
Hospital setting, India
Interventions 2 h prior to procedure, women received either 1) 400 µg sublingual misoprostol or 2) 125 µg IM of 15-
m-PG F2a
Outcomes Side-effects, cervical dilation, need for further dilation, blood loss, satsifaction
Notes No uterine perforations occurred.
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Yes A- adequate
Vimala, Mittal 2004
Methods Randomised controlled trial using random unumber tables and allocated by sequential, opaque, sealed
envelopes
Participants 120 women randomised.
Included women between 6-11 weeks gestation. Excluded women with heart disease, asthma, known
allergy to prostaglandins, multiple pregnancies, or scarred uterus. Ultrasound used to confirm dating
Hospital setting, India
Interventions 2 or 3 h prior to procedure, women received 1) 400 µg sublingual misoprostol or 2) 200 µg sublingual
misoprostol
Outcomes Side- effects, cervical dilation, need for further dilation, blood loss
Notes No uterine perforations or hospitalizations occurred.
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Yes A- adequate
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Wang 1989
Methods Randomised controlled trial
Participants 60 women randomised.
Included nulliparae between 6-11 weeks gestation.
China, unclear setting.
Interventions 12 h prior to procedure, women received: 1) PGF2a 1 mg suppository 2) placebo
Outcomes Cervical dilation, blood loss
Notes Attempted to clarify randomisation and allocation with author but received no response. No cervical
lacerations or uterine perforations occurred
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear Not described
WHO 1986
Methods Randomised controlled trial by computer-generated random number table and allocation by sealed en-
velopes
Participants 627 randomised. Included nulliparae between 8-12weeks gestation, over the legal age of consent. Excluded
women with cardiac disease (past or current), hypertension, respiratory disease, ulcerative colitis, diabetes,
disorders of blood coagulation, kidney disease, liver disease, sickle-cell, history of allergic reactions or any
other serious systemic disease
11 centers in 9 countries (Moscow, Stockholm, New Delhi, Szeged, Ljubljana, Chandigarh, Bombay,
Singapore, Hong Kong, Lusaka, Havana)
Interventions 3-4 hours prior to procedure: 1) 0.5mg IM of 16-phenoxy-tetranor PGE2 methyl sulfonylamide 2) 1 mg
of vaginal 16, 16, dimethyl trans delta2 PGE1 methyl ester 3) 30 mg of vaginal 9 deoxo-16, 16-dimethyl-
9-methylene PGE2 4) 0.5 mg of vaginal 15 methyl-PGF2a methyl ester, or 5) one medium-size laminaria
tent
Outcomes Cervical dilation, need for and ease of further dilation
Notes
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear B- unclear
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WHO 1990
Methods Double-blinded randomised controlled trial by computer-generated random number tables. Allocation
method not described
Participants 230 randomised.
Included nulliparae between 18-35 years with normal general and gynaecologic history and exam and a
living, intrauterine pregnancy between 70-84 days. Excluded women with past cervical surgery or dilation,
or with current signs of threatened abortion and those who wished to start hormonal or intrauterine
contraception within 1 month of abortion. Confirmed dating by ultrasound
6 centers (Aberdeen, Greifswald, Hong Kong, Singapore, Stockholm, Szeged)
Interventions Women received 24 hours and 12 hours prior to procedure one of the following: 1) placebo 2) 25 mg
mifepristone 3) 50 mg mifepristone or 4) 100 mg mifepristone
Outcomes Cervical dilation, ease of dilation, blood loss, side-effects and complications
Notes Four cervical lacerations (randomisation groups not stated) and no uterine perforations occurred. Four
women required reaspiration in the placebo group, as did 1 in the 25 mg mifepristone group
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear B- unclear
Wiebe 1998
Methods Randomised controlled trial using a random number table. Allocation method by sealed envelopes
Participants 93 women randomised.
Included women with first trimester pregnancies
Canada, unclear setting
Interventions 2 h prior to procedure, women received 1) placebo or 2) 750 µg misoprostol vaginally
Outcomes Cervical dilation, pain, side-effects
Notes
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear B- unclear
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Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Bryman 1988 Method of randomisation inadequate
Frankman 1980 Not randomised
Heinzl 1987 Method of randomisation inadequate
Hulka 1987 Did not report on any of our outcomes of interest
Ivy Li 2003 Studied nitric oxide donors, which are excluded from this review (subject of another review)
Khanna 1980 Included women with gestational ages in the second trimester
Platz-Christensen Comparisons were carried out consecutively over time
Saxena 2004 No allocation concealment
Saxena 2006 Method of randomisation inadequate
Skjeldestad 1990 Method of randomisation inadequate
Vengadasalam 1981 Not randomised
Characteristics of ongoing studies [ordered by study ID]
von Hertzen
Trial name or title Pretreatment with misoprostol before vacuum aspiration for first trimester induced abortion
Methods Randomised controlled trial
Participants 4972 women prior to surgical abortion <12 weeks gestation
Interventions Misoprostol 400 µg versus placebo
Outcomes Need for further dilation and adverse events (uterine perforation, cervical laceration)
Starting date 2002
Contact information Helena von Hertzen
Notes completed enrolment in September 2005. Preparation is ongoing and should be forthcoming in the next year,
as per personal communication with Helena von Hertzen
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D A T A A N D A N A L Y S E S
Comparison 1. Misoprostol versus placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Cervical dilation at procedure
start
5 Mean Difference (IV, Fixed, 95% CI) Subtotals only
1.1 Misoprostol 400 µg,
vaginal
2 161 Mean Difference (IV, Fixed, 95% CI) 2.36 [1.92, 2.79]
1.2 Misoprostol 400 µg,
sublingual
1 60 Mean Difference (IV, Fixed, 95% CI) 4.30 [3.53, 5.07]
1.3 Misoprostol 600 µg, oral 1 30 Mean Difference (IV, Fixed, 95% CI) 1.40 [0.51, 2.29]
1.4 Misoprostol 600 µg,
vaginal
1 278 Mean Difference (IV, Fixed, 95% CI) 1.60 [1.14, 2.06]
2 Side-effects: occurrence of
nausea
4 539 Odds Ratio (M-H, Fixed, 95% CI) 1.71 [1.10, 2.66]
2.1 Misoprostol 400 µg,
vaginal
2 201 Odds Ratio (M-H, Fixed, 95% CI) 2.35 [1.11, 4.98]
2.2 Misoprostol 400 µg,
sublingual
1 60 Odds Ratio (M-H, Fixed, 95% CI) 31.24 [1.73, 563.16]
2.3 Misoprostol 600 µg,
vaginal
1 278 Odds Ratio (M-H, Fixed, 95% CI) 0.97 [0.53, 1.80]
3 Procedure length (minutes) 3 Mean Difference (IV, Fixed, 95% CI) Subtotals only
3.1 Misoprostol 400 µg,
vaginal
2 161 Mean Difference (IV, Fixed, 95% CI) -0.68 [-1.17, -0.19]
3.2 Misoprostol, 400 µg,
sublingual
1 60 Mean Difference (IV, Fixed, 95% CI) -3.5 [-4.69, -2.31]
Comparison 2. Gemeprost 1 mg versus placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Need for additional mechanical
dilation
3 349 Odds Ratio (M-H, Random, 95% CI) 0.04 [0.00, 0.51]
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Comparison 3. Mifepristone versus placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Need for additional mechanical
dilation
3 168 Odds Ratio (M-H, Fixed, 95% CI) 0.33 [0.13, 0.82]
1.1 100 mg mifepristone 1 108 Odds Ratio (M-H, Fixed, 95% CI) 0.65 [0.10, 4.08]
1.2 200 mg mifepristone 1 30 Odds Ratio (M-H, Fixed, 95% CI) 0.58 [0.14, 2.48]
1.3 600 mg mifepristone 1 30 Odds Ratio (M-H, Fixed, 95% CI) 0.09 [0.02, 0.50]
2 Cervical dilation at procedure
start
4 232 Mean Difference (IV, Fixed, 95% CI) 1.82 [1.40, 2.24]
2.1 100 mg mifepristone 1 108 Mean Difference (IV, Fixed, 95% CI) 1.40 [0.66, 2.14]
2.2 200 mg mifepristone 2 94 Mean Difference (IV, Fixed, 95% CI) 2.02 [1.51, 2.52]
2.3 600 mg mifepristone 1 30 Mean Difference (IV, Fixed, 95% CI) Not estimable
Comparison 4. Prostaglandin F2α versus placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Need for additional mechanical
dilation
1 287 Odds Ratio (M-H, Fixed, 95% CI) 0.02 [0.01, 0.04]
Comparison 5. Prostaglandin E2 versus placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Need for additional mechanical
dilation
4 Odds Ratio (M-H, Fixed, 95% CI) Subtotals only
1.1 1 mg prostaglandin E2,
intracervical
1 40 Odds Ratio (M-H, Fixed, 95% CI) Not estimable
1.2 25 µg 15 methyl PGE2
methyl ester, extra-amniotic
1 50 Odds Ratio (M-H, Fixed, 95% CI) Not estimable
1.3 1 mg PGE2, oral 1 288 Odds Ratio (M-H, Fixed, 95% CI) 0.23 [0.12, 0.43]
1.4 0.5 mg prostaglandin E2 1 50 Odds Ratio (M-H, Fixed, 95% CI) 0.09 [0.02, 0.35]
2 Cervical dilation at procedure
start
2 328 Mean Difference (IV, Fixed, 95% CI) 6.8 [5.99, 7.61]
2.1 1 mg prostaglandin E2,
intracervical
1 40 Mean Difference (IV, Fixed, 95% CI) 6.8 [5.99, 7.61]
2.2 1 mg prostaglandin E2,
oral
1 288 Mean Difference (IV, Fixed, 95% CI) Not estimable
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Comparison 6. Osmotic dilators versus placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Cervical dilation at procedure
start
1 40 Mean Difference (IV, Fixed, 95% CI) Not estimable
Comparison 7. Misoprostol dose: 400 µg misoprostol versus 200 µg misoprostol
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Cervical dilation at procedure
start
4 Mean Difference (IV, Fixed, 95% CI) Subtotals only
1.1 Oral misoprostol 2 632 Mean Difference (IV, Fixed, 95% CI) 0.53 [0.30, 0.77]
1.2 Vaginal misoprostol 2 137 Mean Difference (IV, Fixed, 95% CI) 0.92 [0.53, 1.31]
1.3 Sublingual misoprostol 1 120 Mean Difference (IV, Fixed, 95% CI) 2.20 [1.61, 2.79]
2 Need for additional mechanical
dilation
2 180 Odds Ratio (M-H, Fixed, 95% CI) 0.04 [0.02, 0.10]
2.1 Vaginal misoprostol 1 60 Odds Ratio (M-H, Fixed, 95% CI) 0.01 [0.00, 0.09]
2.2 Sublingual misoprostol 1 120 Odds Ratio (M-H, Fixed, 95% CI) 0.07 [0.03, 0.17]
3 Pain with cervical priming 2 180 Odds Ratio (M-H, Fixed, 95% CI) 2.50 [1.31, 4.75]
3.1 Vaginal misoprostol 1 60 Odds Ratio (M-H, Fixed, 95% CI) 8.11 [1.61, 40.77]
3.2 Sublingual misoprostol 1 120 Odds Ratio (M-H, Fixed, 95% CI) 1.84 [0.89, 3.80]
4 Procedure length (minutes) 2 197 Mean Difference (IV, Fixed, 95% CI) -1.22 [-1.72, -0.71]
4.1 Vaginal misoprostol 1 77 Mean Difference (IV, Fixed, 95% CI) -0.30 [-1.34, 0.74]
4.2 Sublingual misoprostol 1 120 Mean Difference (IV, Fixed, 95% CI) -1.50 [-2.08, -0.92]
Comparison 8. Interval between misoprostol application and procedure: 2 hours versus 3 hours
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Cervical dilation at procedure
start
1 60 Mean Difference (IV, Fixed, 95% CI) 1.5 [1.42, 1.58]
2 Need for additional mechanical
dilation
1 60 Odds Ratio (M-H, Fixed, 95% CI) 0.01 [0.00, 0.08]
3 Pain with cervical priming 1 60 Odds Ratio (M-H, Fixed, 95% CI) 0.10 [0.02, 0.39]
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Comparison 9. Route of misoprostol administration
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Cervical dilation at procedure
start
5 Mean Difference (IV, Fixed, 95% CI) Subtotals only
1.1 400 µg vaginal versus oral 2 157 Mean Difference (IV, Fixed, 95% CI) 0.50 [0.13, 0.87]
1.2 400 µg vaginal versus
sublingual
3 1604 Mean Difference (IV, Fixed, 95% CI) -0.10 [-0.19, -0.01]
2 Need for additional mechanical
dilation
3 Odds Ratio (M-H, Fixed, 95% CI) Subtotals only
2.1 400 µg vaginal versus oral 1 80 Odds Ratio (M-H, Fixed, 95% CI) 0.47 [0.08, 2.75]
2.2 400 µg vaginal versus
sublingual
2 1524 Odds Ratio (M-H, Fixed, 95% CI) 1.41 [1.15, 1.73]
3 Side-effects: occurrence of
nausea
6 Odds Ratio (M-H, Fixed, 95% CI) Subtotals only
3.1 400 µg vaginal versus oral 2 157 Odds Ratio (M-H, Fixed, 95% CI) 0.59 [0.26, 1.37]
3.2 400 µg vaginal versus
sublingual
4 1678 Odds Ratio (M-H, Fixed, 95% CI) 0.32 [0.23, 0.46]
4 Cervical dilation at procedure
start
1 32 Mean Difference (IV, Fixed, 95% CI) 0.5 [-0.55, 1.55]
5 Procedure length (minutes) 4 Mean Difference (IV, Fixed, 95% CI) Subtotals only
5.1 400 µg vaginal versus oral 2 157 Mean Difference (IV, Fixed, 95% CI) -0.23 [-0.61, 0.15]
5.2 400 µg vaginal versus
sublingual
2 1524 Mean Difference (IV, Fixed, 95% CI) 0.38 [0.11, 0.65]
6 Patient disatisfaction 1 73 Odds Ratio (M-H, Fixed, 95% CI) 0.10 [0.01, 1.97]
Comparison 10. Misoprostol versus gemeprost
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Cervical dilation at procedure
start
3 342 Mean Difference (IV, Fixed, 95% CI) 0.47 [0.10, 0.85]
1.1 400 µg misoprostol versus
1 mg gemeprost
2 154 Mean Difference (IV, Fixed, 95% CI) 0.53 [0.03, 1.04]
1.2 200 µg misoprostol versus
1 mg gemeprost
1 188 Mean Difference (IV, Fixed, 95% CI) 0.40 [-0.16, 0.96]
2 Side-effects of 200 µg
misoprostol versus gemeprost
1 564 Odds Ratio (M-H, Fixed, 95% CI) 0.35 [0.18, 0.68]
2.1 Nausea 1 188 Odds Ratio (M-H, Fixed, 95% CI) 0.41 [0.17, 1.01]
2.2 Vomiting 1 188 Odds Ratio (M-H, Fixed, 95% CI) 0.35 [0.09, 1.35]
2.3 Diarrhea 1 188 Odds Ratio (M-H, Fixed, 95% CI) 0.23 [0.05, 1.11]
3 Side-effects of 400 misoprostol
versus gemeprost
1 128 Odds Ratio (M-H, Fixed, 95% CI) 0.47 [0.11, 1.98]
3.1 Nausea 1 64 Odds Ratio (M-H, Fixed, 95% CI) 0.36 [0.06, 2.01]
3.2 Vomiting 1 64 Odds Ratio (M-H, Fixed, 95% CI) 1.0 [0.06, 16.71]
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4 Procedure length (minutes) 1 64 Mean Difference (IV, Fixed, 95% CI) -1.5 [-3.00, 0.00]
Comparison 11. Misoprostol versus mifepristone
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Cervical dilation at procedure
start
2 90 Mean Difference (IV, Fixed, 95% CI) -0.79 [-1.29, -0.30]
1.1 800 µg misoprostol versus
200 mg mifepristone
1 60 Mean Difference (IV, Fixed, 95% CI) -0.70 [-1.30, -0.10]
1.2 600 µg misoprostol versus
400 mg mifepristone (divided
doses)
1 30 Mean Difference (IV, Fixed, 95% CI) -1.0 [-1.89, -0.11]
2 Side-effects: nausea and vomiting 2 90 Odds Ratio (M-H, Fixed, 95% CI) 0.75 [0.17, 3.33]
2.1 800 µg misoprostol versus
200 µg mifepristone
1 60 Odds Ratio (M-H, Fixed, 95% CI) 0.19 [0.01, 4.06]
2.2 600 µg misoprostol versus
400 mg mifepristone (divided
doses)
1 30 Odds Ratio (M-H, Fixed, 95% CI) 1.63 [0.23, 11.46]
Comparison 12. Misoprostol versus laminaria
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Need for additional mechanical
dilation
2 131 Odds Ratio (M-H, Fixed, 95% CI) 1.04 [0.48, 2.26]
1.1 200 µg misoprostol 1 70 Odds Ratio (M-H, Fixed, 95% CI) 1.18 [0.43, 3.25]
1.2 400 µg misoprostol 1 61 Odds Ratio (M-H, Fixed, 95% CI) 0.88 [0.27, 2.90]
2 Procedure length (minutes) 1 70 Mean Difference (IV, Fixed, 95% CI) -0.10 [-1.09, 0.89]
3 Patient disatisfaction 1 70 Odds Ratio (M-H, Fixed, 95% CI) 0.31 [0.12, 0.84]
Comparison 13. Misoprostol versus prostaglandin F2α
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Need for additional mechanical
dilation
1 60 Odds Ratio (M-H, Fixed, 95% CI) 0.48 [0.16, 1.41]
2 Cervical dilation at procedure
start
1 60 Mean Difference (IV, Fixed, 95% CI) 1.80 [1.04, 2.56]
3 Side-effects: nausea and vomiting 1 60 Odds Ratio (M-H, Fixed, 95% CI) 0.14 [0.02, 1.23]
4 Procedure length (minutes) 1 60 Mean Difference (IV, Fixed, 95% CI) 0.20 [-0.76, 1.16]
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5 Patient disatisfaction 1 60 Odds Ratio (M-H, Fixed, 95% CI) 0.23 [0.04, 1.24]
Comparison 14. Gemeprost 1 mg versus Lamicel
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Need for additional mechanical
dilation
2 153 Odds Ratio (M-H, Fixed, 95% CI) 0.86 [0.38, 1.95]
2 Side-effects 2 Odds Ratio (M-H, Fixed, 95% CI) Subtotals only
2.1 Nausea 2 153 Odds Ratio (M-H, Fixed, 95% CI) 6.89 [0.83, 57.41]
2.2 Pre-operative pain 2 153 Odds Ratio (M-H, Fixed, 95% CI) 3.53 [1.40, 8.90]
Comparison 15. Gemeprost versus Dilapan
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Need for additional mechanical
dilation
2 83 Odds Ratio (M-H, Fixed, 95% CI) 0.87 [0.32, 2.36]
2 Side-effects 2 Odds Ratio (M-H, Fixed, 95% CI) Subtotals only
2.1 Nausea 2 83 Odds Ratio (M-H, Fixed, 95% CI) 0.50 [0.10, 2.51]
2.2 Pre-operative pain 2 83 Odds Ratio (M-H, Fixed, 95% CI) 1.02 [0.37, 2.84]
Comparison 16. Gemeprost versus laminaria
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Need for additional mechanical
dilation
1 250 Odds Ratio (M-H, Fixed, 95% CI) 0.56 [0.29, 1.07]
2 Cervical dilation at procedure
start
1 250 Mean Difference (IV, Fixed, 95% CI) 0.5 [0.05, 0.95]
3 Side-effects: nausea and vomiting 1 250 Odds Ratio (M-H, Fixed, 95% CI) 18.16 [1.04, 318.09]
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Comparison 17. Gemeprost versus prostaglandin F2α
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Need for additional mechanical
dilation
1 252 Odds Ratio (M-H, Fixed, 95% CI) 0.31 [0.15, 0.66]
2 Cervical dilation at procedure
start
1 252 Mean Difference (IV, Fixed, 95% CI) 0.90 [0.42, 1.38]
3 Side-effects: nausea and vomiting 1 252 Odds Ratio (M-H, Fixed, 95% CI) 1.67 [0.53, 5.25]
Comparison 18. Dose of mifepristone
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Need for additional mechanical
dilation
1 102 Odds Ratio (M-H, Fixed, 95% CI) 0.74 [0.12, 4.62]
2 Cervical dilation at procedure
start
1 102 Mean Difference (IV, Fixed, 95% CI) Not estimable
Comparison 19. Laminaria versus prostaglandin F2α
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Cervical dilation at procedure
start
1 40 Mean Difference (IV, Fixed, 95% CI) Not estimable
2 Unplanned expulsion prior to
procedure
1 40 Odds Ratio (M-H, Fixed, 95% CI) 0.07 [0.00, 1.34]
Comparison 20. Laminaria versus sulprostone
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Cervical dilation at procedure
start
1 251 Mean Difference (IV, Fixed, 95% CI) -0.80 [-1.27, -0.33]
2 Need for additional mechanical
dilation
1 251 Odds Ratio (M-H, Fixed, 95% CI) 2.38 [1.26, 4.47]
3 Side-effects: nausea and vomiting 1 251 Odds Ratio (M-H, Fixed, 95% CI) 0.02 [0.00, 0.39]
45Cervical preparation for first trimester surgical abortion (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Comparison 21. Laminaria versus PGE2
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Cervical dilation at procedure
start
1 249 Mean Difference (IV, Fixed, 95% CI) -0.40 [-0.81, 0.01]
2 Need for additional mechanical
dilation
1 249 Odds Ratio (M-H, Fixed, 95% CI) 1.81 [0.95, 3.48]
3 Side-effects: nausea and vomiting 1 249 Odds Ratio (M-H, Fixed, 95% CI) 0.03 [0.00, 0.51]
Comparison 22. Sulprostone versus sulprostone (intracervical doses)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Need for additional mechanical
dilation
1 40 Odds Ratio (M-H, Fixed, 95% CI) Not estimable
2 Side-effects: nausea and vomiting 2 60 Odds Ratio (M-H, Fixed, 95% CI) 0.79 [0.21, 3.04]
3 Unplanned expulsion prior to
procedure
2 60 Odds Ratio (M-H, Fixed, 95% CI) 0.04 [0.00, 0.37]
Comparison 23. Sulprostone versus sulprostone (intramuscular doses)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Need for additional mechanical
dilation
1 200 Odds Ratio (M-H, Fixed, 95% CI) 0.72 [0.24, 2.15]
2 Side-effects: nausea and vomiting 1 200 Odds Ratio (M-H, Fixed, 95% CI) 0.13 [0.04, 0.44]
3 Unplanned expulsion prior to
procedure
1 200 Odds Ratio (M-H, Fixed, 95% CI) 0.34 [0.01, 8.36]
Comparison 24. Prostaglandin E2 versus prostaglandin F2α
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Need for additional mechanical
dilation
1 299 Odds Ratio (M-H, Fixed, 95% CI) 12.9 [7.22, 23.05]
2 Side-effects: nausea and vomiting 1 299 Odds Ratio (M-H, Fixed, 95% CI) 0.17 [0.04, 0.78]
3 Unplanned expulsion prior to
procedure
1 299 Odds Ratio (M-H, Fixed, 95% CI) Not estimable
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Comparison 25. Lamicel versus synthetic sponge without MgSO4
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Unplanned expulsion prior to
procedure
1 41 Odds Ratio (M-H, Fixed, 95% CI) 3.65 [0.14, 94.97]
Analysis 1.1. Comparison 1 Misoprostol versus placebo, Outcome 1 Cervical dilation at procedure start.
Review: Cervical preparation for first trimester surgical abortion
Comparison: 1 Misoprostol versus placebo
Outcome: 1 Cervical dilation at procedure start
Study or subgroup Misoprostol Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Misoprostol 400 g, vaginal
Cakir 2005 40 7.2 (0.8) 40 3.6 (1.9) 45.9 % 3.60 [ 2.96, 4.24 ]
Ngai 1999 37 6.8 (1.3) 44 5.5 (1.4) 54.1 % 1.30 [ 0.71, 1.89 ]
Subtotal (95% CI) 77 84 100.0 % 2.36 [ 1.92, 2.79 ]
Heterogeneity: Chi2 = 26.93, df = 1 (P<0.00001); I2 =96%
Test for overall effect: Z = 10.67 (P < 0.00001)
2 Misoprostol 400 g, sublingual
Vimala 2003 30 7.7 (1.3) 30 3.4 (1.7) 100.0 % 4.30 [ 3.53, 5.07 ]
Subtotal (95% CI) 30 30 100.0 % 4.30 [ 3.53, 5.07 ]
Heterogeneity: not applicable
Test for overall effect: Z = 11.01 (P < 0.00001)
3 Misoprostol 600 g, oral
Bokstrom 1998 15 5.9 (1.5) 15 4.5 (0.9) 100.0 % 1.40 [ 0.51, 2.29 ]
Subtotal (95% CI) 15 15 100.0 % 1.40 [ 0.51, 2.29 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.10 (P = 0.0019)
4 Misoprostol 600 g, vaginal
de Jonge 2000 135 7.6 (2.1) 143 6 (1.8) 100.0 % 1.60 [ 1.14, 2.06 ]
Subtotal (95% CI) 135 143 100.0 % 1.60 [ 1.14, 2.06 ]
Heterogeneity: not applicable
Test for overall effect: Z = 6.80 (P < 0.00001)
Test for subgroup differences: Chi2 = 38.93, df = 3 (P = 0.00), I2 =92%
-10 -5 0 5 10
Favours placebo Favours misoprostol
47Cervical preparation for first trimester surgical abortion (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 1.2. Comparison 1 Misoprostol versus placebo, Outcome 2 Side-effects: occurrence of nausea.
Review: Cervical preparation for first trimester surgical abortion
Comparison: 1 Misoprostol versus placebo
Outcome: 2 Side-effects: occurrence of nausea
Study or subgroup Misoprostol Placebo Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Misoprostol 400 g, vaginal
Cakir 2005 19/40 18/80 21.2 % 3.12 [ 1.38, 7.02 ]
Ngai 1999 0/37 2/44 7.6 % 0.23 [ 0.01, 4.87 ]
Subtotal (95% CI) 77 124 28.9 % 2.35 [ 1.11, 4.98 ]
Total events: 19 (Misoprostol), 20 (Placebo)
Heterogeneity: Chi2 = 2.69, df = 1 (P = 0.10); I2 =63%
Test for overall effect: Z = 2.24 (P = 0.025)
2 Misoprostol 400 g, sublingual
Vimala 2003 10/30 0/30 1.1 % 31.24 [ 1.73, 563.16 ]
Subtotal (95% CI) 30 30 1.1 % 31.24 [ 1.73, 563.16 ]
Total events: 10 (Misoprostol), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 2.33 (P = 0.020)
3 Misoprostol 600 g, vaginal
de Jonge 2000 24/135 26/143 70.0 % 0.97 [ 0.53, 1.80 ]
Subtotal (95% CI) 135 143 70.0 % 0.97 [ 0.53, 1.80 ]
Total events: 24 (Misoprostol), 26 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.09 (P = 0.93)
Total (95% CI) 242 297 100.0 % 1.71 [ 1.10, 2.66 ]
Total events: 53 (Misoprostol), 46 (Placebo)
Heterogeneity: Chi2 = 10.89, df = 3 (P = 0.01); I2 =72%
Test for overall effect: Z = 2.36 (P = 0.018)
Test for subgroup differences: Chi2 = 0.0, df = 2 (P = 0.0), I2 =0.0%
0.01 0.1 1 10 100
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Analysis 1.3. Comparison 1 Misoprostol versus placebo, Outcome 3 Procedure length (minutes).
Review: Cervical preparation for first trimester surgical abortion
Comparison: 1 Misoprostol versus placebo
Outcome: 3 Procedure length (minutes)
Study or subgroup Misoprostol Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Misoprostol 400 g, vaginal
Cakir 2005 40 3.8 (0.9) 40 4.8 (1.7) 68.1 % -1.00 [ -1.60, -0.40 ]
Ngai 1999 37 4.9 (1.9) 44 4.9 (2.1) 31.9 % 0.0 [ -0.87, 0.87 ]
Subtotal (95% CI) 77 84 100.0 % -0.68 [ -1.17, -0.19 ]
Heterogeneity: Chi2 = 3.44, df = 1 (P = 0.06); I2 =71%
Test for overall effect: Z = 2.71 (P = 0.0066)
2 Misoprostol, 400 g, sublingual
Vimala 2003 30 5 (2.4) 30 8.5 (2.3) 100.0 % -3.50 [ -4.69, -2.31 ]
Subtotal (95% CI) 30 30 100.0 % -3.50 [ -4.69, -2.31 ]
Heterogeneity: not applicable
Test for overall effect: Z = 5.77 (P < 0.00001)
Test for subgroup differences: Chi2 = 18.42, df = 1 (P = 0.00), I2 =95%
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Analysis 2.1. Comparison 2 Gemeprost 1 mg versus placebo, Outcome 1 Need for additional mechanical
dilation.
Review: Cervical preparation for first trimester surgical abortion
Comparison: 2 Gemeprost 1 mg versus placebo
Outcome: 1 Need for additional mechanical dilation
Study or subgroup Gemeprost Placebo Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Christensen 1984 10/65 63/64 31.4 % 0.00 [ 0.00, 0.02 ]
Ho 1983 37/58 48/53 37.3 % 0.18 [ 0.06, 0.53 ]
Rabe 1985 46/55 53/54 31.3 % 0.10 [ 0.01, 0.79 ]
Total (95% CI) 178 171 100.0 % 0.04 [ 0.00, 0.51 ]
Total events: 93 (Gemeprost), 164 (Placebo)
Heterogeneity: Tau2 = 4.20; Chi2 = 12.94, df = 2 (P = 0.002); I2 =85%
Test for overall effect: Z = 2.47 (P = 0.013)
0.05 0.2 1 5 20
Favours gemeprost Favours control
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Analysis 3.1. Comparison 3 Mifepristone versus placebo, Outcome 1 Need for additional mechanical
dilation.
Review: Cervical preparation for first trimester surgical abortion
Comparison: 3 Mifepristone versus placebo
Outcome: 1 Need for additional mechanical dilation
Study or subgroup Mifepristone Control Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 100 mg mifepristone
WHO 1990 (1) 51/54 52/54 17.5 % 0.65 [ 0.10, 4.08 ]
Subtotal (95% CI) 54 54 17.5 % 0.65 [ 0.10, 4.08 ]
Total events: 51 (Mifepristone), 52 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.45 (P = 0.65)
2 200 mg mifepristone
Bokstrom 1998 6/15 8/15 29.1 % 0.58 [ 0.14, 2.48 ]
Subtotal (95% CI) 15 15 29.1 % 0.58 [ 0.14, 2.48 ]
Total events: 6 (Mifepristone), 8 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.73 (P = 0.47)
3 600 mg mifepristone
Gupta 1990 4/15 12/15 53.4 % 0.09 [ 0.02, 0.50 ]
Subtotal (95% CI) 15 15 53.4 % 0.09 [ 0.02, 0.50 ]
Total events: 4 (Mifepristone), 12 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 2.75 (P = 0.0059)
Total (95% CI) 84 84 100.0 % 0.33 [ 0.13, 0.82 ]
Total events: 61 (Mifepristone), 72 (Control)
Heterogeneity: Chi2 = 3.32, df = 2 (P = 0.19); I2 =40%
Test for overall effect: Z = 2.38 (P = 0.017)
Test for subgroup differences: Chi2 = 0.0, df = 2 (P = 0.0), I2 =0.0%
0.01 0.1 1 10 100
Favours control Favours mifepristone
(1) 100 mg given 24 and 12 hours prior to procedure
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Analysis 3.2. Comparison 3 Mifepristone versus placebo, Outcome 2 Cervical dilation at procedure start.
Review: Cervical preparation for first trimester surgical abortion
Comparison: 3 Mifepristone versus placebo
Outcome: 2 Cervical dilation at procedure start
Study or subgroup Mifepristone Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 100 mg mifepristone
WHO 1990 54 6.6 (1.9) 54 5.2 (2) 32.1 % 1.40 [ 0.66, 2.14 ]
Subtotal (95% CI) 54 54 32.1 % 1.40 [ 0.66, 2.14 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.73 (P = 0.00019)
2 200 mg mifepristone
Bokstrom 1998 15 6.9 (0.9) 15 4.5 (0.9) 41.9 % 2.40 [ 1.76, 3.04 ]
Durlot 1988 32 5.5 (1.9) 32 4.1 (1.4) 26.0 % 1.40 [ 0.58, 2.22 ]
Subtotal (95% CI) 47 47 67.9 % 2.02 [ 1.51, 2.52 ]
Heterogeneity: Chi2 = 3.55, df = 1 (P = 0.06); I2 =72%
Test for overall effect: Z = 7.81 (P < 0.00001)
3 600 mg mifepristone
Gupta 1990 15 5 (0) 15 3 (0) Not estimable
Subtotal (95% CI) 15 15 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
Total (95% CI) 116 116 100.0 % 1.82 [ 1.40, 2.24 ]
Heterogeneity: Chi2 = 5.38, df = 2 (P = 0.07); I2 =63%
Test for overall effect: Z = 8.55 (P < 0.00001)
Test for subgroup differences: Chi2 = 1.83, df = 1 (P = 0.18), I2 =45%
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Analysis 4.1. Comparison 4 Prostaglandin F2α versus placebo, Outcome 1 Need for additional mechanical
dilation.
Review: Cervical preparation for first trimester surgical abortion
Comparison: 4 Prostaglandin F2 versus placebo
Outcome: 1 Need for additional mechanical dilation
Study or subgroup Prostaglandin F
2
Placebo Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Heinzl 1981 (1) 20/149 124/138 100.0 % 0.02 [ 0.01, 0.04 ]
Total (95% CI) 149 138 100.0 % 0.02 [ 0.01, 0.04 ]
Total events: 20 (Prostaglandin F
2
), 124 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 10.92 (P < 0.00001)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours prostaglandin F
2
Favours placebo
(1) Data from vaginal application of 2.5 mg prostaglandin
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Analysis 5.1. Comparison 5 Prostaglandin E2 versus placebo, Outcome 1 Need for additional mechanical
dilation.
Review: Cervical preparation for first trimester surgical abortion
Comparison: 5 Prostaglandin E2 versus placebo
Outcome: 1 Need for additional mechanical dilation
Study or subgroup Prostaglandin E2 Control Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 1 mg prostaglandin E2 , intracervical
Shalev 1988 1/20 20/20 100.0 % 0.00 [ 0.00, 0.05 ]
Subtotal (95% CI) 20 20 100.0 % 0.00 [ 0.00, 0.05 ]
Total events: 1 (Prostaglandin E2), 20 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 3.77 (P = 0.00016)
2 25 g 15 methyl PGE2 methyl ester, extra-amniotic
Cheng 1975 3/25 25/25 100.0 % 0.00 [ 0.00, 0.06 ]
Subtotal (95% CI) 25 25 100.0 % 0.00 [ 0.00, 0.06 ]
Total events: 3 (Prostaglandin E2), 25 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 3.76 (P = 0.00017)
3 1 mg PGE2, oral
Heinzl 1981 100/150 124/138 100.0 % 0.23 [ 0.12, 0.43 ]
Subtotal (95% CI) 150 138 100.0 % 0.23 [ 0.12, 0.43 ]
Total events: 100 (Prostaglandin E2), 124 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 4.50 (P < 0.00001)
4 0.5 mg prostaglandin E2
Osmers 1990 4/25 17/25 100.0 % 0.09 [ 0.02, 0.35 ]
Subtotal (95% CI) 25 25 100.0 % 0.09 [ 0.02, 0.35 ]
Total events: 4 (Prostaglandin E2), 17 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 3.48 (P = 0.00051)
0.01 0.1 1 10 100
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Analysis 5.2. Comparison 5 Prostaglandin E2 versus placebo, Outcome 2 Cervical dilation at procedure
start.
Review: Cervical preparation for first trimester surgical abortion
Comparison: 5 Prostaglandin E2 versus placebo
Outcome: 2 Cervical dilation at procedure start
Study or subgroup Prostaglandin E2 Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 1 mg prostaglandin E2 , intracervical
Shalev 1988 20 11.2 (0.73) 20 4.4 (1.7) 100.0 % 6.80 [ 5.99, 7.61 ]
Subtotal (95% CI) 20 20 100.0 % 6.80 [ 5.99, 7.61 ]
Heterogeneity: not applicable
Test for overall effect: Z = 16.44 (P < 0.00001)
2 1 mg prostaglandin E2 , oral
Heinzl 1981 150 7 (0) 138 5.6 (0) Not estimable
Subtotal (95% CI) 150 138 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
Total (95% CI) 170 158 100.0 % 6.80 [ 5.99, 7.61 ]
Heterogeneity: not applicable
Test for overall effect: Z = 16.44 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 6.1. Comparison 6 Osmotic dilators versus placebo, Outcome 1 Cervical dilation at procedure
start.
Review: Cervical preparation for first trimester surgical abortion
Comparison: 6 Osmotic dilators versus placebo
Outcome: 1 Cervical dilation at procedure start
Study or subgroup Osmotic dilators Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Morris 1986 20 8.1 (0) 20 4.9 (0) Not estimable
Total (95% CI) 20 20 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Not applicable
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Analysis 7.1. Comparison 7 Misoprostol dose: 400 µg misoprostol versus 200 µg misoprostol, Outcome 1
Cervical dilation at procedure start.
Review: Cervical preparation for first trimester surgical abortion
Comparison: 7 Misoprostol dose: 400 g misoprostol versus 200 g misoprostol
Outcome: 1 Cervical dilation at procedure start
Study or subgroup Higher dose Lower dose
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Oral misoprostol
Ngai 1999 40 7.2 (1) 43 6.6 (0.9) 32.4 % 0.60 [ 0.19, 1.01 ]
Oppegaard 2004 275 5.9 (1.7) 274 5.4 (1.7) 67.6 % 0.50 [ 0.22, 0.78 ]
Subtotal (95% CI) 315 317 100.0 % 0.53 [ 0.30, 0.77 ]
Heterogeneity: Chi2 = 0.15, df = 1 (P = 0.69); I2 =0.0%
Test for overall effect: Z = 4.46 (P < 0.00001)
2 Vaginal misoprostol
Ngai 1999 37 6.8 (1.3) 40 6.8 (1.2) 48.7 % 0.0 [ -0.56, 0.56 ]
Singh 1998 30 8.2 (0.8) 30 6.4 (1.3) 51.3 % 1.80 [ 1.25, 2.35 ]
Subtotal (95% CI) 67 70 100.0 % 0.92 [ 0.53, 1.31 ]
Heterogeneity: Chi2 = 20.33, df = 1 (P<0.00001); I2 =95%
Test for overall effect: Z = 4.62 (P < 0.00001)
3 Sublingual misoprostol
Vimala, Mittal 2004 60 8.2 (2) 60 6 (1.2) 100.0 % 2.20 [ 1.61, 2.79 ]
Subtotal (95% CI) 60 60 100.0 % 2.20 [ 1.61, 2.79 ]
Heterogeneity: not applicable
Test for overall effect: Z = 7.31 (P < 0.00001)
Test for subgroup differences: Chi2 = 27.03, df = 2 (P = 0.00), I2 =93%
-10 -5 0 5 10
Favours 200 g Favours 400 g
57Cervical preparation for first trimester surgical abortion (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 7.2. Comparison 7 Misoprostol dose: 400 µg misoprostol versus 200 µg misoprostol, Outcome 2
Need for additional mechanical dilation.
Review: Cervical preparation for first trimester surgical abortion
Comparison: 7 Misoprostol dose: 400 g misoprostol versus 200 g misoprostol
Outcome: 2 Need for additional mechanical dilation
Study or subgroup Higher dose Lower dose Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Vaginal misoprostol
Singh 1998 1/30 23/30 38.6 % 0.01 [ 0.00, 0.09 ]
Subtotal (95% CI) 30 30 38.6 % 0.01 [ 0.00, 0.09 ]
Total events: 1 (Higher dose), 23 (Lower dose)
Heterogeneity: not applicable
Test for overall effect: Z = 4.12 (P = 0.000037)
2 Sublingual misoprostol
Vimala, Mittal 2004 7/60 40/60 61.4 % 0.07 [ 0.03, 0.17 ]
Subtotal (95% CI) 60 60 61.4 % 0.07 [ 0.03, 0.17 ]
Total events: 7 (Higher dose), 40 (Lower dose)
Heterogeneity: not applicable
Test for overall effect: Z = 5.59 (P < 0.00001)
Total (95% CI) 90 90 100.0 % 0.04 [ 0.02, 0.10 ]
Total events: 8 (Higher dose), 63 (Lower dose)
Heterogeneity: Chi2 = 2.37, df = 1 (P = 0.12); I2 =58%
Test for overall effect: Z = 7.21 (P < 0.00001)
Test for subgroup differences: Chi2 = 0.0, df = 1 (P = 0.0), I2 =0.0%
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Analysis 7.3. Comparison 7 Misoprostol dose: 400 µg misoprostol versus 200 µg misoprostol, Outcome 3
Pain with cervical priming.
Review: Cervical preparation for first trimester surgical abortion
Comparison: 7 Misoprostol dose: 400 g misoprostol versus 200 g misoprostol
Outcome: 3 Pain with cervical priming
Study or subgroup Higher dose Lower dose Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Vaginal misoprostol
Singh 1998 11/30 2/30 10.6 % 8.11 [ 1.61, 40.77 ]
Subtotal (95% CI) 30 30 10.6 % 8.11 [ 1.61, 40.77 ]
Total events: 11 (Higher dose), 2 (Lower dose)
Heterogeneity: not applicable
Test for overall effect: Z = 2.54 (P = 0.011)
2 Sublingual misoprostol
Vimala, Mittal 2004 37/60 28/60 89.4 % 1.84 [ 0.89, 3.80 ]
Subtotal (95% CI) 60 60 89.4 % 1.84 [ 0.89, 3.80 ]
Total events: 37 (Higher dose), 28 (Lower dose)
Heterogeneity: not applicable
Test for overall effect: Z = 1.64 (P = 0.10)
Total (95% CI) 90 90 100.0 % 2.50 [ 1.31, 4.75 ]
Total events: 48 (Higher dose), 30 (Lower dose)
Heterogeneity: Chi2 = 2.72, df = 1 (P = 0.10); I2 =63%
Test for overall effect: Z = 2.79 (P = 0.0052)
Test for subgroup differences: Chi2 = 0.0, df = 1 (P = 0.0), I2 =0.0%
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Analysis 7.4. Comparison 7 Misoprostol dose: 400 µg misoprostol versus 200 µg misoprostol, Outcome 4
Procedure length (minutes).
Review: Cervical preparation for first trimester surgical abortion
Comparison: 7 Misoprostol dose: 400 g misoprostol versus 200 g misoprostol
Outcome: 4 Procedure length (minutes)
Study or subgroup Higher dose Lower dose
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Vaginal misoprostol
Ngai 1999 37 4.9 (1.9) 40 5.2 (2.7) 23.6 % -0.30 [ -1.34, 0.74 ]
Subtotal (95% CI) 37 40 23.6 % -0.30 [ -1.34, 0.74 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.57 (P = 0.57)
2 Sublingual misoprostol
Vimala, Mittal 2004 60 3.1 (1.4) 60 4.6 (1.8) 76.4 % -1.50 [ -2.08, -0.92 ]
Subtotal (95% CI) 60 60 76.4 % -1.50 [ -2.08, -0.92 ]
Heterogeneity: not applicable
Test for overall effect: Z = 5.10 (P < 0.00001)
Total (95% CI) 97 100 100.0 % -1.22 [ -1.72, -0.71 ]
Heterogeneity: Chi2 = 3.93, df = 1 (P = 0.05); I2 =75%
Test for overall effect: Z = 4.73 (P < 0.00001)
Test for subgroup differences: Chi2 = 3.93, df = 1 (P = 0.05), I2 =75%
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Analysis 8.1. Comparison 8 Interval between misoprostol application and procedure: 2 hours versus 3
hours, Outcome 1 Cervical dilation at procedure start.
Review: Cervical preparation for first trimester surgical abortion
Comparison: 8 Interval between misoprostol application and procedure: 2 hours versus 3 hours
Outcome: 1 Cervical dilation at procedure start
Study or subgroup 3 hours 2 hours
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Singh 1999 (1) 30 8.1 (0.1) 30 6.6 (0.2) 100.0 % 1.50 [ 1.42, 1.58 ]
Total (95% CI) 30 30 100.0 % 1.50 [ 1.42, 1.58 ]
Heterogeneity: not applicable
Test for overall effect: Z = 36.74 (P < 0.00001)
Test for subgroup differences: Not applicable
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(1) 400 g vaginal misoprostol 3 hours prior, and 600 g vaginal misoprostol 2 hours prior
Analysis 8.2. Comparison 8 Interval between misoprostol application and procedure: 2 hours versus 3
hours, Outcome 2 Need for additional mechanical dilation.
Review: Cervical preparation for first trimester surgical abortion
Comparison: 8 Interval between misoprostol application and procedure: 2 hours versus 3 hours
Outcome: 2 Need for additional mechanical dilation
Study or subgroup 3 hours 2 hours Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Singh 1999 (1) 2/30 25/30 100.0 % 0.01 [ 0.00, 0.08 ]
Total (95% CI) 30 30 100.0 % 0.01 [ 0.00, 0.08 ]
Total events: 2 (3 hours), 25 (2 hours)
Heterogeneity: not applicable
Test for overall effect: Z = 4.82 (P < 0.00001)
Test for subgroup differences: Not applicable
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(1) 400 g vaginal misoprostol used 3 hours prior and 600 g used 2 hours prior
Analysis 8.3. Comparison 8 Interval between misoprostol application and procedure: 2 hours versus 3
hours, Outcome 3 Pain with cervical priming.
Review: Cervical preparation for first trimester surgical abortion
Comparison: 8 Interval between misoprostol application and procedure: 2 hours versus 3 hours
Outcome: 3 Pain with cervical priming
Study or subgroup 3 hours 2 hours Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Singh 1999 3/30 16/30 100.0 % 0.10 [ 0.02, 0.39 ]
Total (95% CI) 30 30 100.0 % 0.10 [ 0.02, 0.39 ]
Total events: 3 (3 hours), 16 (2 hours)
Heterogeneity: not applicable
Test for overall effect: Z = 3.28 (P = 0.0010)
Test for subgroup differences: Not applicable
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Analysis 9.1. Comparison 9 Route of misoprostol administration, Outcome 1 Cervical dilation at procedure
start.
Review: Cervical preparation for first trimester surgical abortion
Comparison: 9 Route of misoprostol administration
Outcome: 1 Cervical dilation at procedure start
Study or subgroup Vaginal Oral
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 400 g vaginal versus oral
Cakir 2005 40 7.2 (0.8) 40 6.6 (1.5) 49.4 % 0.60 [ 0.07, 1.13 ]
Ngai 1999 40 7.2 (1) 37 6.8 (1.3) 50.6 % 0.40 [ -0.12, 0.92 ]
Subtotal (95% CI) 80 77 100.0 % 0.50 [ 0.13, 0.87 ]
Heterogeneity: Chi2 = 0.28, df = 1 (P = 0.60); I2 =0.0%
Test for overall effect: Z = 2.64 (P = 0.0083)
2 400 g vaginal versus sublingual
Esteve 2006 708 6.7 (0.9) 716 6.8 (0.8) 96.0 % -0.10 [ -0.19, -0.01 ]
Tang 2004 40 7.7 (0.73) 40 7.6 (1.3) 3.5 % 0.10 [ -0.36, 0.56 ]
Vimala 2004 50 6.8 (2.6) 50 8.6 (4) 0.4 % -1.80 [ -3.12, -0.48 ]
Subtotal (95% CI) 798 806 100.0 % -0.10 [ -0.19, -0.01 ]
Heterogeneity: Chi2 = 7.07, df = 2 (P = 0.03); I2 =72%
Test for overall effect: Z = 2.27 (P = 0.023)
Test for subgroup differences: Chi2 = 9.53, df = 1 (P = 0.00), I2 =90%
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Analysis 9.2. Comparison 9 Route of misoprostol administration, Outcome 2 Need for additional
mechanical dilation.
Review: Cervical preparation for first trimester surgical abortion
Comparison: 9 Route of misoprostol administration
Outcome: 2 Need for additional mechanical dilation
Study or subgroup Vaginal Oral/ Sublingual Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 400 g vaginal versus oral
Cakir 2005 2/40 4/40 100.0 % 0.47 [ 0.08, 2.75 ]
Subtotal (95% CI) 40 40 100.0 % 0.47 [ 0.08, 2.75 ]
Total events: 2 (Vaginal), 4 (Oral/ Sublingual)
Heterogeneity: not applicable
Test for overall effect: Z = 0.83 (P = 0.40)
2 400 g vaginal versus sublingual
Esteve 2006 448/708 402/716 96.1 % 1.35 [ 1.09, 1.66 ]
Vimala 2004 23/50 11/50 3.9 % 3.02 [ 1.27, 7.21 ]
Subtotal (95% CI) 758 766 100.0 % 1.41 [ 1.15, 1.73 ]
Total events: 471 (Vaginal), 413 (Oral/ Sublingual)
Heterogeneity: Chi2 = 3.13, df = 1 (P = 0.08); I2 =68%
Test for overall effect: Z = 3.28 (P = 0.0010)
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Analysis 9.3. Comparison 9 Route of misoprostol administration, Outcome 3 Side-effects: occurrence of
nausea.
Review: Cervical preparation for first trimester surgical abortion
Comparison: 9 Route of misoprostol administration
Outcome: 3 Side-effects: occurrence of nausea
Study or subgroup Vaginal Oral Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 400 g vaginal versus oral
Cakir 2005 19/40 23/40 83.6 % 0.67 [ 0.28, 1.62 ]
Ngai 1999 0/37 2/40 16.4 % 0.21 [ 0.01, 4.42 ]
Subtotal (95% CI) 77 80 100.0 % 0.59 [ 0.26, 1.37 ]
Total events: 19 (Vaginal), 25 (Oral)
Heterogeneity: Chi2 = 0.53, df = 1 (P = 0.47); I2 =0.0%
Test for overall effect: Z = 1.23 (P = 0.22)
2 400 g vaginal versus sublingual
Esteve 2006 18/708 89/716 73.4 % 0.18 [ 0.11, 0.31 ]
Hamoda 2004 11/37 22/37 13.1 % 0.29 [ 0.11, 0.76 ]
Tang 2004 14/40 8/40 4.4 % 2.15 [ 0.78, 5.92 ]
Vimala 2004 (1) 9/50 13/50 9.1 % 0.62 [ 0.24, 1.63 ]
Subtotal (95% CI) 835 843 100.0 % 0.32 [ 0.23, 0.46 ]
Total events: 52 (Vaginal), 132 (Oral)
Heterogeneity: Chi2 = 19.94, df = 3 (P = 0.00017); I2 =85%
Test for overall effect: Z = 6.16 (P < 0.00001)
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Analysis 9.4. Comparison 9 Route of misoprostol administration, Outcome 4 Cervical dilation at procedure
start.
Review: Cervical preparation for first trimester surgical abortion
Comparison: 9 Route of misoprostol administration
Outcome: 4 Cervical dilation at procedure start
Study or subgroup Sublingual Oral
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Aronsson 2004 15 7.5 (1.2) 17 7 (1.8) 100.0 % 0.50 [ -0.55, 1.55 ]
Total (95% CI) 15 17 100.0 % 0.50 [ -0.55, 1.55 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.93 (P = 0.35)
Test for subgroup differences: Not applicable
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Analysis 9.5. Comparison 9 Route of misoprostol administration, Outcome 5 Procedure length (minutes).
Review: Cervical preparation for first trimester surgical abortion
Comparison: 9 Route of misoprostol administration
Outcome: 5 Procedure length (minutes)
Study or subgroup Vaginal Oral
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 400 g vaginal versus oral
Cakir 2005 40 3.8 (0.9) 40 3.9 (1) 83.5 % -0.10 [ -0.52, 0.32 ]
Ngai 1999 37 4.9 (1.9) 40 5.8 (2.3) 16.5 % -0.90 [ -1.84, 0.04 ]
Subtotal (95% CI) 77 80 100.0 % -0.23 [ -0.61, 0.15 ]
Heterogeneity: Chi2 = 2.33, df = 1 (P = 0.13); I2 =57%
Test for overall effect: Z = 1.19 (P = 0.23)
2 400 g vaginal versus sublingual
Esteve 2006 708 7.4 (2.5) 716 7 (2.8) 94.2 % 0.40 [ 0.12, 0.68 ]
Vimala 2004 50 3.16 (3.6) 50 3.08 (1.8) 5.8 % 0.08 [ -1.04, 1.20 ]
Subtotal (95% CI) 758 766 100.0 % 0.38 [ 0.11, 0.65 ]
Heterogeneity: Chi2 = 0.30, df = 1 (P = 0.59); I2 =0.0%
Test for overall effect: Z = 2.79 (P = 0.0052)
Test for subgroup differences: Chi2 = 6.66, df = 1 (P = 0.01), I2 =85%
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Analysis 9.6. Comparison 9 Route of misoprostol administration, Outcome 6 Patient disatisfaction.
Review: Cervical preparation for first trimester surgical abortion
Comparison: 9 Route of misoprostol administration
Outcome: 6 Patient disatisfaction
Study or subgroup Vaginal Sublingual Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Hamoda 2004 0/36 4/37 100.0 % 0.10 [ 0.01, 1.97 ]
Total (95% CI) 36 37 100.0 % 0.10 [ 0.01, 1.97 ]
Total events: 0 (Vaginal), 4 (Sublingual)
Heterogeneity: not applicable
Test for overall effect: Z = 1.51 (P = 0.13)
Test for subgroup differences: Not applicable
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Analysis 10.1. Comparison 10 Misoprostol versus gemeprost, Outcome 1 Cervical dilation at procedure
start.
Review: Cervical preparation for first trimester surgical abortion
Comparison: 10 Misoprostol versus gemeprost
Outcome: 1 Cervical dilation at procedure start
Study or subgroup Misoprostol Gemeprost
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 400 g misoprostol versus 1 mg gemeprost
Ekerhovd 2003 45 7.6 (1.6) 45 7.4 (1.5) 34.4 % 0.20 [ -0.44, 0.84 ]
Ngai, Yeung 1995 32 8.1 (1.7) 32 7 (1.7) 20.4 % 1.10 [ 0.27, 1.93 ]
Subtotal (95% CI) 77 77 54.8 % 0.53 [ 0.03, 1.04 ]
Heterogeneity: Chi2 = 2.82, df = 1 (P = 0.09); I2 =65%
Test for overall effect: Z = 2.06 (P = 0.039)
2 200 g misoprostol versus 1 mg gemeprost
Henry 1999 95 7.1 (2.1) 93 6.7 (1.8) 45.2 % 0.40 [ -0.16, 0.96 ]
Subtotal (95% CI) 95 93 45.2 % 0.40 [ -0.16, 0.96 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.40 (P = 0.16)
Total (95% CI) 172 170 100.0 % 0.47 [ 0.10, 0.85 ]
Heterogeneity: Chi2 = 2.94, df = 2 (P = 0.23); I2 =32%
Test for overall effect: Z = 2.47 (P = 0.013)
Test for subgroup differences: Chi2 = 0.12, df = 1 (P = 0.73), I2 =0.0%
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Analysis 10.2. Comparison 10 Misoprostol versus gemeprost, Outcome 2 Side-effects of 200 µg misoprostol
versus gemeprost.
Review: Cervical preparation for first trimester surgical abortion
Comparison: 10 Misoprostol versus gemeprost
Outcome: 2 Side-effects of 200 g misoprostol versus gemeprost
Study or subgroup Misoprostol Gemeprost Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Nausea
Henry 1999 8/95 17/93 50.0 % 0.41 [ 0.17, 1.01 ]
Subtotal (95% CI) 95 93 50.0 % 0.41 [ 0.17, 1.01 ]
Total events: 8 (Misoprostol), 17 (Gemeprost)
Heterogeneity: not applicable
Test for overall effect: Z = 1.95 (P = 0.052)
2 Vomiting
Henry 1999 3/95 8/93 24.9 % 0.35 [ 0.09, 1.35 ]
Subtotal (95% CI) 95 93 24.9 % 0.35 [ 0.09, 1.35 ]
Total events: 3 (Misoprostol), 8 (Gemeprost)
Heterogeneity: not applicable
Test for overall effect: Z = 1.53 (P = 0.13)
3 Diarrhea
Henry 1999 2/95 8/93 25.1 % 0.23 [ 0.05, 1.11 ]
Subtotal (95% CI) 95 93 25.1 % 0.23 [ 0.05, 1.11 ]
Total events: 2 (Misoprostol), 8 (Gemeprost)
Heterogeneity: not applicable
Test for overall effect: Z = 1.83 (P = 0.067)
Total (95% CI) 285 279 100.0 % 0.35 [ 0.18, 0.68 ]
Total events: 13 (Misoprostol), 33 (Gemeprost)
Heterogeneity: Chi2 = 0.41, df = 2 (P = 0.82); I2 =0.0%
Test for overall effect: Z = 3.07 (P = 0.0021)
Test for subgroup differences: Chi2 = 0.0, df = 2 (P = 0.0), I2 =0.0%
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Analysis 10.3. Comparison 10 Misoprostol versus gemeprost, Outcome 3 Side-effects of 400 misoprostol
versus gemeprost.
Review: Cervical preparation for first trimester surgical abortion
Comparison: 10 Misoprostol versus gemeprost
Outcome: 3 Side-effects of 400 misoprostol versus gemeprost
Study or subgroup Misoprostol Gemeprost Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Nausea
Ngai, Yeung 1995 2/32 5/32 82.9 % 0.36 [ 0.06, 2.01 ]
Subtotal (95% CI) 32 32 82.9 % 0.36 [ 0.06, 2.01 ]
Total events: 2 (Misoprostol), 5 (Gemeprost)
Heterogeneity: not applicable
Test for overall effect: Z = 1.16 (P = 0.24)
2 Vomiting
Ngai, Yeung 1995 1/32 1/32 17.1 % 1.00 [ 0.06, 16.71 ]
Subtotal (95% CI) 32 32 17.1 % 1.00 [ 0.06, 16.71 ]
Total events: 1 (Misoprostol), 1 (Gemeprost)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
Total (95% CI) 64 64 100.0 % 0.47 [ 0.11, 1.98 ]
Total events: 3 (Misoprostol), 6 (Gemeprost)
Heterogeneity: Chi2 = 0.37, df = 1 (P = 0.54); I2 =0.0%
Test for overall effect: Z = 1.03 (P = 0.30)
Test for subgroup differences: Chi2 = 0.0, df = 1 (P = 0.0), I2 =0.0%
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Analysis 10.4. Comparison 10 Misoprostol versus gemeprost, Outcome 4 Procedure length (minutes).
Review: Cervical preparation for first trimester surgical abortion
Comparison: 10 Misoprostol versus gemeprost
Outcome: 4 Procedure length (minutes)
Study or subgroup Misoprostol Gemeprost
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Ngai, Yeung 1995 32 5.5 (2.7) 32 7 (3.4) 100.0 % -1.50 [ -3.00, 0.00 ]
Total (95% CI) 32 32 100.0 % -1.50 [ -3.00, 0.00 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.95 (P = 0.051)
Test for subgroup differences: Not applicable
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Analysis 11.1. Comparison 11 Misoprostol versus mifepristone, Outcome 1 Cervical dilation at procedure
start.
Review: Cervical preparation for first trimester surgical abortion
Comparison: 11 Misoprostol versus mifepristone
Outcome: 1 Cervical dilation at procedure start
Study or subgroup Misoprostol Mifepristone
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 800 g misoprostol versus 200 mg mifepristone
Ashok 2000 (1) 30 7.6 (1.4) 30 8.3 (0.9) 68.8 % -0.70 [ -1.30, -0.10 ]
Subtotal (95% CI) 30 30 68.8 % -0.70 [ -1.30, -0.10 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.30 (P = 0.021)
2 600 g misoprostol versus 400 mg mifepristone (divided doses)
Bokstrom 1998 (2) 15 5.9 (1.5) 15 6.9 (0.9) 31.2 % -1.00 [ -1.89, -0.11 ]
Subtotal (95% CI) 15 15 31.2 % -1.00 [ -1.89, -0.11 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.21 (P = 0.027)
Total (95% CI) 45 45 100.0 % -0.79 [ -1.29, -0.30 ]
Heterogeneity: Chi2 = 0.30, df = 1 (P = 0.58); I2 =0.0%
Test for overall effect: Z = 3.15 (P = 0.0016)
Test for subgroup differences: Chi2 = 0.30, df = 1 (P = 0.58), I2 =0.0%
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Analysis 11.2. Comparison 11 Misoprostol versus mifepristone, Outcome 2 Side-effects: nausea and
vomiting.
Review: Cervical preparation for first trimester surgical abortion
Comparison: 11 Misoprostol versus mifepristone
Outcome: 2 Side-effects: nausea and vomiting
Study or subgroup Misoprostol Mifepristone Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 800 g misoprostol versus 200 g mifepristone
Ashok 2000 0/30 2/30 60.6 % 0.19 [ 0.01, 4.06 ]
Subtotal (95% CI) 30 30 60.6 % 0.19 [ 0.01, 4.06 ]
Total events: 0 (Misoprostol), 2 (Mifepristone)
Heterogeneity: not applicable
Test for overall effect: Z = 1.07 (P = 0.29)
2 600 g misoprostol versus 400 mg mifepristone (divided doses)
Bokstrom 1998 3/15 2/15 39.4 % 1.63 [ 0.23, 11.46 ]
Subtotal (95% CI) 15 15 39.4 % 1.63 [ 0.23, 11.46 ]
Total events: 3 (Misoprostol), 2 (Mifepristone)
Heterogeneity: not applicable
Test for overall effect: Z = 0.49 (P = 0.63)
Total (95% CI) 45 45 100.0 % 0.75 [ 0.17, 3.33 ]
Total events: 3 (Misoprostol), 4 (Mifepristone)
Heterogeneity: Chi2 = 1.38, df = 1 (P = 0.24); I2 =28%
Test for overall effect: Z = 0.37 (P = 0.71)
Test for subgroup differences: Chi2 = 0.0, df = 1 (P = 0.0), I2 =0.0%
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Analysis 12.1. Comparison 12 Misoprostol versus laminaria, Outcome 1 Need for additional mechanical
dilation.
Review: Cervical preparation for first trimester surgical abortion
Comparison: 12 Misoprostol versus laminaria
Outcome: 1 Need for additional mechanical dilation
Study or subgroup Misoprostol Laminaria Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 200 g misoprostol
Burnett 2005 26/37 22/33 54.6 % 1.18 [ 0.43, 3.25 ]
Subtotal (95% CI) 37 33 54.6 % 1.18 [ 0.43, 3.25 ]
Total events: 26 (Misoprostol), 22 (Laminaria)
Heterogeneity: not applicable
Test for overall effect: Z = 0.32 (P = 0.75)
2 400 g misoprostol
MacIsaac 1999 22/47 7/14 45.4 % 0.88 [ 0.27, 2.90 ]
Subtotal (95% CI) 47 14 45.4 % 0.88 [ 0.27, 2.90 ]
Total events: 22 (Misoprostol), 7 (Laminaria)
Heterogeneity: not applicable
Test for overall effect: Z = 0.21 (P = 0.83)
Total (95% CI) 84 47 100.0 % 1.04 [ 0.48, 2.26 ]
Total events: 48 (Misoprostol), 29 (Laminaria)
Heterogeneity: Chi2 = 0.14, df = 1 (P = 0.71); I2 =0.0%
Test for overall effect: Z = 0.11 (P = 0.91)
Test for subgroup differences: Chi2 = 0.0, df = 1 (P = 0.0), I2 =0.0%
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Analysis 12.2. Comparison 12 Misoprostol versus laminaria, Outcome 2 Procedure length (minutes).
Review: Cervical preparation for first trimester surgical abortion
Comparison: 12 Misoprostol versus laminaria
Outcome: 2 Procedure length (minutes)
Study or subgroup Misoprostol Laminaria
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Burnett 2005 37 3.8 (2.5) 33 3.9 (1.7) 100.0 % -0.10 [ -1.09, 0.89 ]
Total (95% CI) 37 33 100.0 % -0.10 [ -1.09, 0.89 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.20 (P = 0.84)
Test for subgroup differences: Not applicable
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Analysis 12.3. Comparison 12 Misoprostol versus laminaria, Outcome 3 Patient disatisfaction.
Review: Cervical preparation for first trimester surgical abortion
Comparison: 12 Misoprostol versus laminaria
Outcome: 3 Patient disatisfaction
Study or subgroup Misoprostol Laminaria Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Burnett 2005 (1) 11/37 19/33 100.0 % 0.31 [ 0.12, 0.84 ]
Total (95% CI) 37 33 100.0 % 0.31 [ 0.12, 0.84 ]
Total events: 11 (Misoprostol), 19 (Laminaria)
Heterogeneity: not applicable
Test for overall effect: Z = 2.32 (P = 0.021)
Test for subgroup differences: Not applicable
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(1) Satisfaction measured by the woman’s answer to question: would you have the same dilating device again?
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Analysis 13.1. Comparison 13 Misoprostol versus prostaglandin F2α, Outcome 1 Need for additional
mechanical dilation.
Review: Cervical preparation for first trimester surgical abortion
Comparison: 13 Misoprostol versus prostaglandin F
2
Outcome: 1 Need for additional mechanical dilation
Study or subgroup Misoprostol Prostaglandin F
2
Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Vimala 2005 8/30 13/30 100.0 % 0.48 [ 0.16, 1.41 ]
Total (95% CI) 30 30 100.0 % 0.48 [ 0.16, 1.41 ]
Total events: 8 (Misoprostol), 13 (Prostaglandin F
2
)
Heterogeneity: not applicable
Test for overall effect: Z = 1.34 (P = 0.18)
Test for subgroup differences: Not applicable
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Analysis 13.2. Comparison 13 Misoprostol versus prostaglandin F2α, Outcome 2 Cervical dilation at
procedure start.
Review: Cervical preparation for first trimester surgical abortion
Comparison: 13 Misoprostol versus prostaglandin F
2
Outcome: 2 Cervical dilation at procedure start
Study or subgroup Misoprostol Prostaglandin F
2
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Vimala 2005 30 8.8 (1.6) 30 7 (1.4) 100.0 % 1.80 [ 1.04, 2.56 ]
Total (95% CI) 30 30 100.0 % 1.80 [ 1.04, 2.56 ]
Heterogeneity: not applicable
Test for overall effect: Z = 4.64 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 13.3. Comparison 13 Misoprostol versus prostaglandin F2α, Outcome 3 Side-effects: nausea and
vomiting.
Review: Cervical preparation for first trimester surgical abortion
Comparison: 13 Misoprostol versus prostaglandin F
2
Outcome: 3 Side-effects: nausea and vomiting
Study or subgroup Misoprostol Prostaglandin F
2
Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Vimala 2005 1/30 6/30 100.0 % 0.14 [ 0.02, 1.23 ]
Total (95% CI) 30 30 100.0 % 0.14 [ 0.02, 1.23 ]
Total events: 1 (Misoprostol), 6 (Prostaglandin F
2
)
Heterogeneity: not applicable
Test for overall effect: Z = 1.78 (P = 0.076)
Test for subgroup differences: Not applicable
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Analysis 13.4. Comparison 13 Misoprostol versus prostaglandin F2α, Outcome 4 Procedure length
(minutes).
Review: Cervical preparation for first trimester surgical abortion
Comparison: 13 Misoprostol versus prostaglandin F
2
Outcome: 4 Procedure length (minutes)
Study or subgroup Misoprostol Prostaglandin F
2
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Vimala 2005 30 3.8 (2) 30 3.6 (1.8) 100.0 % 0.20 [ -0.76, 1.16 ]
Total (95% CI) 30 30 100.0 % 0.20 [ -0.76, 1.16 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.41 (P = 0.68)
Test for subgroup differences: Not applicable
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Analysis 13.5. Comparison 13 Misoprostol versus prostaglandin F2α, Outcome 5 Patient disatisfaction.
Review: Cervical preparation for first trimester surgical abortion
Comparison: 13 Misoprostol versus prostaglandin F
2
Outcome: 5 Patient disatisfaction
Study or subgroup Misoprostol Prostaglandin F
2
Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Vimala 2005 2/30 7/30 100.0 % 0.23 [ 0.04, 1.24 ]
Total (95% CI) 30 30 100.0 % 0.23 [ 0.04, 1.24 ]
Total events: 2 (Misoprostol), 7 (Prostaglandin F
2
)
Heterogeneity: not applicable
Test for overall effect: Z = 1.71 (P = 0.088)
Test for subgroup differences: Not applicable
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Analysis 14.1. Comparison 14 Gemeprost 1 mg versus Lamicel, Outcome 1 Need for additional mechanical
dilation.
Review: Cervical preparation for first trimester surgical abortion
Comparison: 14 Gemeprost 1 mg versus Lamicel
Outcome: 1 Need for additional mechanical dilation
Study or subgroup Gemeprost Lamicel Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Golland 1989 18/23 17/22 30.1 % 1.06 [ 0.26, 4.32 ]
Stornes 1991 46/57 43/51 69.9 % 0.78 [ 0.29, 2.12 ]
Total (95% CI) 80 73 100.0 % 0.86 [ 0.38, 1.95 ]
Total events: 64 (Gemeprost), 60 (Lamicel)
Heterogeneity: Chi2 = 0.12, df = 1 (P = 0.73); I2 =0.0%
Test for overall effect: Z = 0.36 (P = 0.72)
Test for subgroup differences: Not applicable
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Analysis 14.2. Comparison 14 Gemeprost 1 mg versus Lamicel, Outcome 2 Side-effects.
Review: Cervical preparation for first trimester surgical abortion
Comparison: 14 Gemeprost 1 mg versus Lamicel
Outcome: 2 Side-effects
Study or subgroup Gemeprost Lamicel Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Nausea
Golland 1989 1/23 0/22 50.1 % 3.00 [ 0.12, 77.64 ]
Stornes 1991 5/57 0/51 49.9 % 10.79 [ 0.58, 200.16 ]
Subtotal (95% CI) 80 73 100.0 % 6.89 [ 0.83, 57.41 ]
Total events: 6 (Gemeprost), 0 (Lamicel)
Heterogeneity: Chi2 = 0.34, df = 1 (P = 0.56); I2 =0.0%
Test for overall effect: Z = 1.78 (P = 0.074)
2 Pre-operative pain
Golland 1989 8/23 7/22 85.7 % 1.14 [ 0.33, 3.95 ]
Stornes 1991 15/57 1/51 14.3 % 17.86 [ 2.26, 140.86 ]
Subtotal (95% CI) 80 73 100.0 % 3.53 [ 1.40, 8.90 ]
Total events: 23 (Gemeprost), 8 (Lamicel)
Heterogeneity: Chi2 = 5.54, df = 1 (P = 0.02); I2 =82%
Test for overall effect: Z = 2.67 (P = 0.0075)
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Analysis 15.1. Comparison 15 Gemeprost versus Dilapan, Outcome 1 Need for additional mechanical
dilation.
Review: Cervical preparation for first trimester surgical abortion
Comparison: 15 Gemeprost versus Dilapan
Outcome: 1 Need for additional mechanical dilation
Study or subgroup Gemeprost Dilapan Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Golland 1989 7/23 8/20 71.3 % 0.66 [ 0.19, 2.32 ]
Jurgenson 1989 17/20 16/20 28.7 % 1.42 [ 0.27, 7.34 ]
Total (95% CI) 43 40 100.0 % 0.87 [ 0.32, 2.36 ]
Total events: 24 (Gemeprost), 24 (Dilapan)
Heterogeneity: Chi2 = 0.53, df = 1 (P = 0.47); I2 =0.0%
Test for overall effect: Z = 0.26 (P = 0.79)
Test for subgroup differences: Not applicable
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Analysis 15.2. Comparison 15 Gemeprost versus Dilapan, Outcome 2 Side-effects.
Review: Cervical preparation for first trimester surgical abortion
Comparison: 15 Gemeprost versus Dilapan
Outcome: 2 Side-effects
Study or subgroup Gemeprost Dilapan Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Nausea
Golland 1989 1/23 0/20 11.6 % 2.73 [ 0.11, 70.92 ]
Jurgenson 1989 1/20 4/20 88.4 % 0.21 [ 0.02, 2.08 ]
Subtotal (95% CI) 43 40 100.0 % 0.50 [ 0.10, 2.51 ]
Total events: 2 (Gemeprost), 4 (Dilapan)
Heterogeneity: Chi2 = 1.59, df = 1 (P = 0.21); I2 =37%
Test for overall effect: Z = 0.84 (P = 0.40)
2 Pre-operative pain
Golland 1989 8/23 4/20 38.3 % 2.13 [ 0.53, 8.58 ]
Jurgenson 1989 15/20 18/20 61.7 % 0.33 [ 0.06, 1.97 ]
Subtotal (95% CI) 43 40 100.0 % 1.02 [ 0.37, 2.84 ]
Total events: 23 (Gemeprost), 22 (Dilapan)
Heterogeneity: Chi2 = 2.60, df = 1 (P = 0.11); I2 =62%
Test for overall effect: Z = 0.04 (P = 0.97)
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Analysis 16.1. Comparison 16 Gemeprost versus laminaria, Outcome 1 Need for additional mechanical
dilation.
Review: Cervical preparation for first trimester surgical abortion
Comparison: 16 Gemeprost versus laminaria
Outcome: 1 Need for additional mechanical dilation
Study or subgroup Gemeprost Laminaria Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
WHO 1986 96/125 107/125 100.0 % 0.56 [ 0.29, 1.07 ]
Total (95% CI) 125 125 100.0 % 0.56 [ 0.29, 1.07 ]
Total events: 96 (Gemeprost), 107 (Laminaria)
Heterogeneity: not applicable
Test for overall effect: Z = 1.77 (P = 0.077)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours gemeprost Favours laminaria
Analysis 16.2. Comparison 16 Gemeprost versus laminaria, Outcome 2 Cervical dilation at procedure start.
Review: Cervical preparation for first trimester surgical abortion
Comparison: 16 Gemeprost versus laminaria
Outcome: 2 Cervical dilation at procedure start
Study or subgroup Gemeprost Laminaria
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
WHO 1986 125 7.4 (2.1) 125 6.9 (1.5) 100.0 % 0.50 [ 0.05, 0.95 ]
Total (95% CI) 125 125 100.0 % 0.50 [ 0.05, 0.95 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.17 (P = 0.030)
Test for subgroup differences: Not applicable
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Analysis 16.3. Comparison 16 Gemeprost versus laminaria, Outcome 3 Side-effects: nausea and vomiting.
Review: Cervical preparation for first trimester surgical abortion
Comparison: 16 Gemeprost versus laminaria
Outcome: 3 Side-effects: nausea and vomiting
Study or subgroup Gemeprost Laminaria Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
WHO 1986 8/125 0/125 100.0 % 18.16 [ 1.04, 318.09 ]
Total (95% CI) 125 125 100.0 % 18.16 [ 1.04, 318.09 ]
Total events: 8 (Gemeprost), 0 (Laminaria)
Heterogeneity: not applicable
Test for overall effect: Z = 1.98 (P = 0.047)
Test for subgroup differences: Not applicable
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Analysis 17.1. Comparison 17 Gemeprost versus prostaglandin F2α, Outcome 1 Need for additional
mechanical dilation.
Review: Cervical preparation for first trimester surgical abortion
Comparison: 17 Gemeprost versus prostaglandin F
2
Outcome: 1 Need for additional mechanical dilation
Study or subgroup Gemeprost Prostaglandin F
2
Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
WHO 1986 96/125 116/127 100.0 % 0.31 [ 0.15, 0.66 ]
Total (95% CI) 125 127 100.0 % 0.31 [ 0.15, 0.66 ]
Total events: 96 (Gemeprost), 116 (Prostaglandin F
2
)
Heterogeneity: not applicable
Test for overall effect: Z = 3.05 (P = 0.0023)
Test for subgroup differences: Not applicable
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Analysis 17.2. Comparison 17 Gemeprost versus prostaglandin F2α, Outcome 2 Cervical dilation at
procedure start.
Review: Cervical preparation for first trimester surgical abortion
Comparison: 17 Gemeprost versus prostaglandin F
2
Outcome: 2 Cervical dilation at procedure start
Study or subgroup Gemeprost Prostaglandin F
2
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
WHO 1986 125 7.4 (2.1) 127 6.5 (1.8) 100.0 % 0.90 [ 0.42, 1.38 ]
Total (95% CI) 125 127 100.0 % 0.90 [ 0.42, 1.38 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.65 (P = 0.00026)
Test for subgroup differences: Not applicable
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Analysis 17.3. Comparison 17 Gemeprost versus prostaglandin F2α, Outcome 3 Side-effects: nausea and
vomiting.
Review: Cervical preparation for first trimester surgical abortion
Comparison: 17 Gemeprost versus prostaglandin F
2
Outcome: 3 Side-effects: nausea and vomiting
Study or subgroup Gemeprost Prostaglandin F
2
Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
WHO 1986 8/125 5/127 100.0 % 1.67 [ 0.53, 5.25 ]
Total (95% CI) 125 127 100.0 % 1.67 [ 0.53, 5.25 ]
Total events: 8 (Gemeprost), 5 (Prostaglandin F
2
)
Heterogeneity: not applicable
Test for overall effect: Z = 0.88 (P = 0.38)
Test for subgroup differences: Not applicable
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Analysis 18.1. Comparison 18 Dose of mifepristone, Outcome 1 Need for additional mechanical dilation.
Review: Cervical preparation for first trimester surgical abortion
Comparison: 18 Dose of mifepristone
Outcome: 1 Need for additional mechanical dilation
Study or subgroup
Mifepristone
100 mg x2
Mifepristone
25 mg x2 Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
WHO 1990 51/54 46/48 100.0 % 0.74 [ 0.12, 4.62 ]
Total (95% CI) 54 48 100.0 % 0.74 [ 0.12, 4.62 ]
Total events: 51 (Mifepristone 100 mg x2), 46 (Mifepristone 25 mg x2)
Heterogeneity: not applicable
Test for overall effect: Z = 0.32 (P = 0.75)
Test for subgroup differences: Not applicable
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Analysis 18.2. Comparison 18 Dose of mifepristone, Outcome 2 Cervical dilation at procedure start.
Review: Cervical preparation for first trimester surgical abortion
Comparison: 18 Dose of mifepristone
Outcome: 2 Cervical dilation at procedure start
Study or subgroup
Mifepristone
100 mg x2
Mifepristone
25 mg x2
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
WHO 1990 54 6.6 (1.9) 48 6.6 (1.9) 100.0 % 0.0 [ -0.74, 0.74 ]
Total (95% CI) 54 48 100.0 % 0.0 [ -0.74, 0.74 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
Test for subgroup differences: Not applicable
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Analysis 19.1. Comparison 19 Laminaria versus prostaglandin F2α, Outcome 1 Cervical dilation at
procedure start.
Review: Cervical preparation for first trimester surgical abortion
Comparison: 19 Laminaria versus prostaglandin F
2
Outcome: 1 Cervical dilation at procedure start
Study or subgroup Laminaria Prostaglandin F
2
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Morris 1986 20 8.1 (0) 20 6.5 (0) Not estimable
Total (95% CI) 20 20 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Not applicable
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Analysis 19.2. Comparison 19 Laminaria versus prostaglandin F2α, Outcome 2 Unplanned expulsion prior
to procedure.
Review: Cervical preparation for first trimester surgical abortion
Comparison: 19 Laminaria versus prostaglandin F
2
Outcome: 2 Unplanned expulsion prior to procedure
Study or subgroup Laminaria Prostaglandin F
2
Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Morris 1986 0/20 5/20 100.0 % 0.07 [ 0.00, 1.34 ]
Total (95% CI) 20 20 100.0 % 0.07 [ 0.00, 1.34 ]
Total events: 0 (Laminaria), 5 (Prostaglandin F
2
)
Heterogeneity: not applicable
Test for overall effect: Z = 1.77 (P = 0.077)
Test for subgroup differences: Not applicable
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Analysis 20.1. Comparison 20 Laminaria versus sulprostone, Outcome 1 Cervical dilation at procedure
start.
Review: Cervical preparation for first trimester surgical abortion
Comparison: 20 Laminaria versus sulprostone
Outcome: 1 Cervical dilation at procedure start
Study or subgroup Laminaria Sulprostone
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
WHO 1986 125 6.9 (1.5) 126 7.7 (2.2) 100.0 % -0.80 [ -1.27, -0.33 ]
Total (95% CI) 125 126 100.0 % -0.80 [ -1.27, -0.33 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.37 (P = 0.00076)
Test for subgroup differences: Not applicable
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Analysis 20.2. Comparison 20 Laminaria versus sulprostone, Outcome 2 Need for additional mechanical
dilation.
Review: Cervical preparation for first trimester surgical abortion
Comparison: 20 Laminaria versus sulprostone
Outcome: 2 Need for additional mechanical dilation
Study or subgroup Laminaria Sulprostone Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
WHO 1986 107/125 90/126 100.0 % 2.38 [ 1.26, 4.47 ]
Total (95% CI) 125 126 100.0 % 2.38 [ 1.26, 4.47 ]
Total events: 107 (Laminaria), 90 (Sulprostone)
Heterogeneity: not applicable
Test for overall effect: Z = 2.69 (P = 0.0072)
Test for subgroup differences: Not applicable
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Analysis 20.3. Comparison 20 Laminaria versus sulprostone, Outcome 3 Side-effects: nausea and vomiting.
Review: Cervical preparation for first trimester surgical abortion
Comparison: 20 Laminaria versus sulprostone
Outcome: 3 Side-effects: nausea and vomiting
Study or subgroup Laminaria Sulprostone Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
WHO 1986 0/125 18/126 100.0 % 0.02 [ 0.00, 0.39 ]
Total (95% CI) 125 126 100.0 % 0.02 [ 0.00, 0.39 ]
Total events: 0 (Laminaria), 18 (Sulprostone)
Heterogeneity: not applicable
Test for overall effect: Z = 2.61 (P = 0.0091)
Test for subgroup differences: Not applicable
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Analysis 21.1. Comparison 21 Laminaria versus PGE2, Outcome 1 Cervical dilation at procedure start.
Review: Cervical preparation for first trimester surgical abortion
Comparison: 21 Laminaria versus PGE2
Outcome: 1 Cervical dilation at procedure start
Study or subgroup Laminaria
9 deoxo-16, 16-
dimethyl-9-methylene
PGE2
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
WHO 1986 125 6.9 (1.5) 124 7.3 (1.8) 100.0 % -0.40 [ -0.81, 0.01 ]
Total (95% CI) 125 124 100.0 % -0.40 [ -0.81, 0.01 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.90 (P = 0.057)
Test for subgroup differences: Not applicable
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Analysis 21.2. Comparison 21 Laminaria versus PGE2, Outcome 2 Need for additional mechanical dilation.
Review: Cervical preparation for first trimester surgical abortion
Comparison: 21 Laminaria versus PGE2
Outcome: 2 Need for additional mechanical dilation
Study or subgroup Laminaria
9 deoxo-16, 16-
dimethyl-9-methylene
PGE2 Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
WHO 1986 107/125 95/124 100.0 % 1.81 [ 0.95, 3.48 ]
Total (95% CI) 125 124 100.0 % 1.81 [ 0.95, 3.48 ]
Total events: 107 (Laminaria), 95 (9 deoxo-16, 16-dimethyl-9-methylene PGE2)
Heterogeneity: not applicable
Test for overall effect: Z = 1.80 (P = 0.072)
Test for subgroup differences: Not applicable
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Analysis 21.3. Comparison 21 Laminaria versus PGE2, Outcome 3 Side-effects: nausea and vomiting.
Review: Cervical preparation for first trimester surgical abortion
Comparison: 21 Laminaria versus PGE2
Outcome: 3 Side-effects: nausea and vomiting
Study or subgroup Laminaria
9 deoxo-16, 16-
dimethyl-9-methylene
PGE2 Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
WHO 1986 0/125 14/124 100.0 % 0.03 [ 0.00, 0.51 ]
Total (95% CI) 125 124 100.0 % 0.03 [ 0.00, 0.51 ]
Total events: 0 (Laminaria), 14 (9 deoxo-16, 16-dimethyl-9-methylene PGE2)
Heterogeneity: not applicable
Test for overall effect: Z = 2.42 (P = 0.016)
Test for subgroup differences: Not applicable
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Analysis 22.1. Comparison 22 Sulprostone versus sulprostone (intracervical doses), Outcome 1 Need for
additional mechanical dilation.
Review: Cervical preparation for first trimester surgical abortion
Comparison: 22 Sulprostone versus sulprostone (intracervical doses)
Outcome: 1 Need for additional mechanical dilation
Study or subgroup 50 g sulprostone 100 g sulprostone Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Rath 1985 0/20 0/20 Not estimable
Total (95% CI) 20 20 Not estimable
Total events: 0 (50 g sulprostone), 0 (100 g sulprostone)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Not applicable
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Analysis 22.2. Comparison 22 Sulprostone versus sulprostone (intracervical doses), Outcome 2 Side-
effects: nausea and vomiting.
Review: Cervical preparation for first trimester surgical abortion
Comparison: 22 Sulprostone versus sulprostone (intracervical doses)
Outcome: 2 Side-effects: nausea and vomiting
Study or subgroup 50 g sulprostone 100 g sulprostone Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Rath 1983 0/10 2/10 49.9 % 0.16 [ 0.01, 3.85 ]
Rath 1985 4/20 3/20 50.1 % 1.42 [ 0.27, 7.34 ]
Total (95% CI) 30 30 100.0 % 0.79 [ 0.21, 3.04 ]
Total events: 4 (50 g sulprostone), 5 (100 g sulprostone)
Heterogeneity: Chi2 = 1.44, df = 1 (P = 0.23); I2 =31%
Test for overall effect: Z = 0.34 (P = 0.73)
Test for subgroup differences: Not applicable
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Analysis 22.3. Comparison 22 Sulprostone versus sulprostone (intracervical doses), Outcome 3 Unplanned
expulsion prior to procedure.
Review: Cervical preparation for first trimester surgical abortion
Comparison: 22 Sulprostone versus sulprostone (intracervical doses)
Outcome: 3 Unplanned expulsion prior to procedure
Study or subgroup 50 g sulprostone 100 g sulprostone Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Rath 1983 0/10 7/10 57.1 % 0.02 [ 0.00, 0.50 ]
Rath 1985 0/20 5/20 42.9 % 0.07 [ 0.00, 1.34 ]
Total (95% CI) 30 30 100.0 % 0.04 [ 0.00, 0.37 ]
Total events: 0 (50 g sulprostone), 12 (100 g sulprostone)
Heterogeneity: Chi2 = 0.27, df = 1 (P = 0.61); I2 =0.0%
Test for overall effect: Z = 2.86 (P = 0.0042)
Test for subgroup differences: Not applicable
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Analysis 23.1. Comparison 23 Sulprostone versus sulprostone (intramuscular doses), Outcome 1 Need for
additional mechanical dilation.
Review: Cervical preparation for first trimester surgical abortion
Comparison: 23 Sulprostone versus sulprostone (intramuscular doses)
Outcome: 1 Need for additional mechanical dilation
Study or subgroup 250 g 500 g Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Christensen 1985 91/99 95/101 100.0 % 0.72 [ 0.24, 2.15 ]
Total (95% CI) 99 101 100.0 % 0.72 [ 0.24, 2.15 ]
Total events: 91 (250 g), 95 (500 g)
Heterogeneity: not applicable
Test for overall effect: Z = 0.59 (P = 0.55)
Test for subgroup differences: Not applicable
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Analysis 23.2. Comparison 23 Sulprostone versus sulprostone (intramuscular doses), Outcome 2 Side-
effects: nausea and vomiting.
Review: Cervical preparation for first trimester surgical abortion
Comparison: 23 Sulprostone versus sulprostone (intramuscular doses)
Outcome: 2 Side-effects: nausea and vomiting
Study or subgroup 250 g 500 g Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Christensen 1985 3/99 20/101 100.0 % 0.13 [ 0.04, 0.44 ]
Total (95% CI) 99 101 100.0 % 0.13 [ 0.04, 0.44 ]
Total events: 3 (250 g), 20 (500 g)
Heterogeneity: not applicable
Test for overall effect: Z = 3.24 (P = 0.0012)
Test for subgroup differences: Not applicable
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Analysis 23.3. Comparison 23 Sulprostone versus sulprostone (intramuscular doses), Outcome 3
Unplanned expulsion prior to procedure.
Review: Cervical preparation for first trimester surgical abortion
Comparison: 23 Sulprostone versus sulprostone (intramuscular doses)
Outcome: 3 Unplanned expulsion prior to procedure
Study or subgroup 250 g 500 g Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Christensen 1985 0/99 1/101 100.0 % 0.34 [ 0.01, 8.36 ]
Total (95% CI) 99 101 100.0 % 0.34 [ 0.01, 8.36 ]
Total events: 0 (250 g), 1 (500 g)
Heterogeneity: not applicable
Test for overall effect: Z = 0.66 (P = 0.51)
Test for subgroup differences: Not applicable
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Analysis 24.1. Comparison 24 Prostaglandin E2 versus prostaglandin F2α, Outcome 1 Need for additional
mechanical dilation.
Review: Cervical preparation for first trimester surgical abortion
Comparison: 24 Prostaglandin E2 versus prostaglandin F
2
Outcome: 1 Need for additional mechanical dilation
Study or subgroup Prostaglandin E2 Prostaglandin F
2
Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Heinzl 1981 (1) 100/150 20/149 100.0 % 12.90 [ 7.22, 23.05 ]
Total (95% CI) 150 149 100.0 % 12.90 [ 7.22, 23.05 ]
Total events: 100 (Prostaglandin E2), 20 (Prostaglandin F
2
)
Heterogeneity: not applicable
Test for overall effect: Z = 8.63 (P < 0.00001)
Test for subgroup differences: Not applicable
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(1) 1 mg oral prostaglandins E2 was compared with 2.5 mg intracervical F
2
Analysis 24.2. Comparison 24 Prostaglandin E2 versus prostaglandin F2α, Outcome 2 Side-effects: nausea
and vomiting.
Review: Cervical preparation for first trimester surgical abortion
Comparison: 24 Prostaglandin E2 versus prostaglandin F
2
Outcome: 2 Side-effects: nausea and vomiting
Study or subgroup Prostaglandin E2 Prostaglandin F
2
Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Heinzl 1981 2/150 11/149 100.0 % 0.17 [ 0.04, 0.78 ]
Total (95% CI) 150 149 100.0 % 0.17 [ 0.04, 0.78 ]
Total events: 2 (Prostaglandin E2), 11 (Prostaglandin F
2
)
Heterogeneity: not applicable
Test for overall effect: Z = 2.28 (P = 0.023)
Test for subgroup differences: Not applicable
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Analysis 24.3. Comparison 24 Prostaglandin E2 versus prostaglandin F2α, Outcome 3 Unplanned expulsion
prior to procedure.
Review: Cervical preparation for first trimester surgical abortion
Comparison: 24 Prostaglandin E2 versus prostaglandin F
2
Outcome: 3 Unplanned expulsion prior to procedure
Study or subgroup Prostaglandin E2 Prostaglandin F
2
Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Heinzl 1981 0/150 28/149 100.0 % 0.01 [ 0.00, 0.23 ]
Total (95% CI) 150 149 100.0 % 0.01 [ 0.00, 0.23 ]
Total events: 0 (Prostaglandin E2), 28 (Prostaglandin F
2
)
Heterogeneity: not applicable
Test for overall effect: Z = 2.97 (P = 0.0029)
Test for subgroup differences: Not applicable
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Analysis 25.1. Comparison 25 Lamicel versus synthetic sponge without MgSO4, Outcome 1 Unplanned
expulsion prior to procedure.
Review: Cervical preparation for first trimester surgical abortion
Comparison: 25 Lamicel versus synthetic sponge without MgSO4
Outcome: 1 Unplanned expulsion prior to procedure
Study or subgroup Lamicel Synthetic sponge Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Radestad 1989 1/19 0/22 100.0 % 3.65 [ 0.14, 94.97 ]
Total (95% CI) 19 22 100.0 % 3.65 [ 0.14, 94.97 ]
Total events: 1 (Lamicel), 0 (Synthetic sponge)
Heterogeneity: not applicable
Test for overall effect: Z = 0.78 (P = 0.44)
Test for subgroup differences: Not applicable
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A D D I T I O N A L T A B L E S
Table 1. Placebo versus misoprostol
Study Treatment N Cervical dilation (mm)
Inal 2003 placebo 60 5.9
200 µg oral misoprostol 30 6.5
200 µg vaginal misoprostol 30 6.6
Wiebe 1998 placebo 47 6.2
700 µg vaginal misoprostol 46 6.8
Okanlomo 1999 placebo 66 nulli 2.5
multi 3.9
600 µg vaginal misoprostol 12 h
prior +
400 µg misoprostol 4 h prior
70 nulli 6.0
multi 6.6
Table 2. Placebo versus PGF2α
Study Treatment N Cervical dilation (mm)
Wang 1989 placebo 30 4.3
1 mg supp. PGF2α 30 6.6
Morris 1986 placebo 20 4.9
20 mg PGF2α gel 20 6.5
Table 3. Misoprostol administrative routes
Study Treatment N Cervical dilation (mm)
Oral (or) vs vaginal (v)
Ashok 2003 400 µg or. 32 7.0
800 µg v. 32 7.0
Carbonell 2001 400 µg or. 450 8.1
400 µg v. 450 8.5
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Table 3. Misoprostol administrative routes (Continued)
Inal 2003 200 µg or. 30 6.5
200 µg v. 30 6.5
Oppegaard 2006 400 µg or. 163 6.5
400 µg v. 158 6.2
Vaginal (v) vs sublingual (s)
Hamoda 2004 400 µg v. 37 7.5
400 µg s. 37 8.0
Table 4. Misoprostol versus gemeprost
Study Treatment N Cervical dilation (mm)
El-Rafaey 1994 600 µg misoprostol 30 8.0
1 mg gemeprost 30 8.0
Table 5. PGF2α versus laminaria
Study Treatment N Cervical dilation (mm)
Morris 1986 20 mg PGF2αgel 20 6.5
Laminaria 20 8.1
Table 6. Sulprostone doses
Study Treatment N Cervical dilation (mm)
Rath 1983 0.05 sulprostone gel 10 10
0.1 mg sulprostone gel 10 >10
98Cervical preparation for first trimester surgical abortion (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Table 7. Lamicel versus synthetic sponge
Study Treatment N Cervical dilatation (mm)
Radestad 1989 Lamicel (3mm) 19 4.4
Synthetic sponge (no MgSo4) 22 4.1
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